#BEGIN_DRUGCARD DB03721

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
49026

# Chemical_Formula:
C11H19NO9

# Chemical_IUPAC_Name:
(2S,4R,5S,6S)-5-acetamido-2,4-dihydroxy-6-[(1S,2S)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
An N-acyl derivative of neuraminic acid. N-acetylneuraminic acid occurs in many polysaccharides, glycoproteins, and glycolipids in animals and bacteria. (From Dorland, 28th ed, p1518)

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
O-Sialic Acid

# HET_ID:
SIA

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C11H19NO9/c1-4(14)12-7-5(15)2-11(20,10(18)19)21-9(7)8(17)6(16)3-13/h5-9,13,15-17,20H,2-3H2,1H3,(H,12,14)(H,18,19)/t5-,6+,7+,8+,9+,11+/m1/s1

# InChI_Key:
InChIKey=SQVRNKJHWKZAKO-LLYCPFJPSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3721

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
309.2699

# Molecular_Weight_Mono:
309.105981211

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1DFQ

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.8

# Predicted_LogS:
-0.13

# Predicted_Water_Solubility:
2.27e+02 g/l

# Primary_Accession_No:
DB03721

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
36690637

# PubChem_Substance_ID:
46505298

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02909

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(=O)N[C@H]1[C@H](O)C[C@](O)(O[C@@H]1[C@@H](O)[C@@H](O)CO)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:33 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CES1

# Phase_1_Metabolizing_Enzyme_1_ID:
4604

# Phase_1_Metabolizing_Enzyme_1_Name:
Liver carboxylesterase 1

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Liver carboxylesterase 1
MWLRAFILATLSASAAWGHPSSPPVVDTVHGKVLGKFVSLEGFAQPVAIFLGIPFAKPPL
GPLRFTPPQPAEPWSFVKNATSYPPMCTQDPKAGQLLSELFTNRKENIPLKLSEDCLYLN
IYTPADLTKKNRLPVMVWIHGGGLMVGAASTYDGLALAAHENVVVVTIQYRLGIWGFFST
GDEHSRGNWGHLDQVAALRWVQDNIASFGGNPGSVTIFGESAGGESVSVLVLSPLAKNLF
HRAISESGVALTSVLVKKGDVKPLAEQIAITAGCKTTTSAVMVHCLRQKTEEELLETTLK
MKFLSLDLQGDPRESQPLLGTVIDGMLLLKTPEELQAERNFHTVPYMVGINKQEFGWLIP
MQLMSYPLSEGQLDQKTAMSLLWKSYPLVCIAKELIPEATEKYLGGTDDTVKKKDLFLDL
IADVMFGVPSVIVARNHRDAGAPTYMYEFQYRPSFSSDMKPKTVIGDHGDELFSVFGAPF
LKEGASEEEIRLSKMVMKFWANFARNGNPNGEGLPHWPEYNQKEGYLQIGANTQAAQKLK
DKEVAFWTNLFAKKAVEKPPQTEHIEL

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P23141

# Drug_Target_10_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
SELP

# Drug_Target_10_GenBank_ID_Gene:
M60234

# Drug_Target_10_GenBank_ID_Protein:
183389

# Drug_Target_10_GeneCard_ID:
SELP

# Drug_Target_10_Gene_Name:
SELP

# Drug_Target_10_Gene_Sequence:
>2493 bp
ATGGCCAACTGCCAAATAGCCATCTTGTACCAGAGATTCCAGAGAGTGGTCTTTGGAATT
TCCCAACTCCTTTGCTTCAGTGCCCTGATCTCTGAACTAACAAACCAGAAAGAAGTGGCA
GCATGGACTTATCATTACAGCACAAAAGCATACTCATGGAATATTTCCCGTAAATACTGC
CAGAATCGCTACACAGACTTAGTGGCCATCCAGAATAAAAATGAAATTGATTACCTCAAT
AAGGTCCTACCCTACTACAGCTCCTACTACTGGATTGGGATCCGAAAGAACAATAAGACA
TGGACATGGGTGGGAACCAAAAAGGCTCTCACCAACGAGGCTGAGAACTGGGCTGATAAT
GAACCTAACAACAAAAGGAACAACGAGGACTGCGTGGAGATATACATCAAGAGTCCGTCA
GCCCCTGGCAAGTGGAATGATGAGCACTGCTTGAAGAAAAAGCACGCATTGTGTTACACA
GCCTCCTGCCAGGACATGTCCTGCAGCAAACAAGGAGAGTGCCTCGAGACCATCGGGAAC
TACACCTGCTCCTGTTACCCTGGATTCTATGGGCCAGAATGTGAATACGTGAGAGAGTGT
GGAGAACTTGAGCTCCCTCAACACGTGCTCATGAACTGCAGCCACCCTCTGGGAAACTTC
TCTTTTAACTCGCAGTGCAGCTTCCACTGCACTGACGGGTACCAAGTAAATGGGCCCAGC
AAGCTGGAATGCTTGGCTTCTGGAATCTGGACAAATAAGCCTCCACAGTGTTTAGCTGCC
CAGTGCCCACCCCTGAAGATTCCTGAACGAGGAAACATGATCTGCCTTCATTCTGCAAAA
GCATTCCAGCATCAGTCTAGCTGCAGCTTCAGTTGTGAAGAGGGATTTGCATTAGTTGGA
CCGGAAGTGGTGCAATGCACAGCCTCGGGGGTATGGACAGCCCCAGCCCCAGTGTGTAAA
GCTGTGCAGTGTCAGCACCTGGAAGCCCCCAGTGAAGGAACCATGGACTGTGTTCATCCG
CTCACTGCTTTTGCCTATGGCTCCAGCTGCAAATTTGAGTGCCAGCCCGGCTACAGAGTG
AGGGGCTTGGACATGCTCCGCTGCATTGACTCTGGACACTGGTCTGCACCCTTGCCAACC
TGTGAGGCTATTTCGTGTGAGCCGCTGGAGAGTCCTGTCCACGGAAGCATGGATTGCTCT
CCATCCTTGAGAGCGTTTCAGTATGACACCAACTGTAGCTTCCGCTGTGCTGAAGGTTTC
ATGCTGAGAGGAGCCGATATAGTTCGGTGTGATAACTTGGGACAGTGGACAGCACCAGCC
CCAGTCTGTCAAGCTTTGCAGTGCCAGGATCTCCCAGTTCCAAATGAGGCCCGGGTGAAC
TGCTCCCACCCCTTCGGTGCCTTTAGGTACCAGTCAGTCTGCAGCTTCACCTGCAATGAA
GGCTTGCTCCTGGTGGGAGCAAGTGTGCTACAGTGCTTGGCTACTGGAAACTGGAATTCT
GTTCCTCCAGAATGCCAAGCCATTCCCTGCACACCTTTGCTAAGCCCTCAGAATGGAACA
ATGACCTGTGTTCAACCTCTTGGAAGTTCCAGTTATAAATCCACATGTCAATTCATCTGT
GACGAGGGATATTCTTTGTCTGGACCAGAAAGATTGGATTGTACTCGATCGGGACGCTGG
ACAGACTCCCCACCAATGTGTGAAGCCATCAAGTGCCCAGAACTCTTTGCCCCAGAGCAG
GGCAGCCTGGATTGTTCTGACACTCGTGGAGAATTCAATGTTGGCTCCACCTGTCATTTC
TCTTGTAACAATGGCTTTAAGCTGGAGGGGCCCAATAATGTGGAATGCACAACTTCTGGA
AGATGGTCAGCTACTCCACCAACCTGCAAAGGCATAGCATCACTTCCTACTCCAGGGTTG
CAATGTCCAGCCCTCACCACTCCTGGGCAGGGAACCATGTACTGTAGGCATCATCCGGGA
ACCTTTGGTTTTAATACCACTTGTTACTTTGGCTGCAACGCTGGATTCACACTCATAGGA
GACAGCACTCTCAGCTGCAGACCTTCAGGACAATGGACAGCAGTAACTCCAGCATGCAGA
GCTGTGAAATGCTCAGAACTACATGTTAATAAGCCAATAGCGATGAACTGCTCCAACCTC
TGGGGAAACTTCAGTTATGGATCAATCTGCTCTTTCCATTGTCTAGAGGGCCAGTTACTT
AATGGCTCTGCACAAACAGCATGCCAAGAGAATGGCCACTGGTCAACTACCGTGCCAACC
TGCCAAGCAGGACCATTGACTATCCAGGAAGCCCTGACTTACTTTGGTGGAGCGGTGGCT
TCTACAATAGGTCTGATAATGGGTGGGACGCTCCTGGCTTTGCTAAGAAAGCGTTTCAGA
CAAAAAGATGATGGGAAATGCCCCTTGAATCCTCACAGCCACCTAGGAACATATGGAGTT
TTTACAAACGCTGCATTTGACCCGAGTCCTTAA

# Drug_Target_10_General_Function:
Involved in sugar binding

# Drug_Target_10_General_References:
10391209	Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999 Jul;22(3):231-8.
11237770	Florian V, Schluter T, Bohnensack R: A new member of the sorting nexin family interacts with the C-terminus of P-selectin. Biochem Biophys Res Commun. 2001 Mar 9;281(4):1045-50.
2466574	Johnston GI, Cook RG, McEver RP: Cloning of GMP-140, a granule membrane protein of platelets and endothelium: sequence similarity to proteins involved in cell adhesion and inflammation. Cell. 1989 Mar 24;56(6):1033-44.
7505680	Bajorath J, Stenkamp R, Aruffo A: Knowledge-based model building of proteins: concepts and examples. Protein Sci. 1993 Nov;2(11):1798-810.
7684381	Fujimoto T, Stroud E, Whatley RE, Prescott SM, Muszbek L, Laposata M, McEver RP: P-selectin is acylated with palmitic acid and stearic acid at cysteine 766 through a thioester linkage. J Biol Chem. 1993 May 25;268(15):11394-400.
8901515	Freedman SJ, Sanford DG, Bachovchin WW, Furie BC, Baleja JD, Furie B: Structure and function of the epidermal growth factor domain of P-selectin. Biochemistry. 1996 Oct 29;35(43):13733-44.
9668170	Herrmann SM, Ricard S, Nicaud V, Mallet C, Evans A, Ruidavets JB, Arveiler D, Luc G, Cambien F: The P-selectin gene is highly polymorphic: reduced frequency of the Pro715 allele carriers in patients with myocardial infarction. Hum Mol Genet. 1998 Aug;7(8):1277-84.

# Drug_Target_10_HGNC_ID:
HGNC:10721

# Drug_Target_10_HPRD_ID:
01433

# Drug_Target_10_ID:
2058

# Drug_Target_10_Locus:
1q22-q25

# Drug_Target_10_Molecular_Weight:
90845

# Drug_Target_10_Name:
P-selectin

# Drug_Target_10_Number_of_Residues:
830

# Drug_Target_10_PDB_ID:
1G1S

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF00008	EGF
PF00059	Lectin_C
PF00084	Sushi

# Drug_Target_10_Protein_Sequence:
>P-selectin precursor
MANCQIAILYQRFQRVVFGISQLLCFSALISELTNQKEVAAWTYHYSTKAYSWNISRKYC
QNRYTDLVAIQNKNEIDYLNKVLPYYSSYYWIGIRKNNKTWTWVGTKKALTNEAENWADN
EPNNKRNNEDCVEIYIKSPSAPGKWNDEHCLKKKHALCYTASCQDMSCSKQGECLETIGN
YTCSCYPGFYGPECEYVRECGELELPQHVLMNCSHPLGNFSFNSQCSFHCTDGYQVNGPS
KLECLASGIWTNKPPQCLAAQCPPLKIPERGNMICLHSAKAFQHQSSCSFSCEEGFALVG
PEVVQCTASGVWTAPAPVCKAVQCQHLEAPSEGTMDCVHPLTAFAYGSSCKFECQPGYRV
RGLDMLRCIDSGHWSAPLPTCEAISCEPLESPVHGSMDCSPSLRAFQYDTNCSFRCAEGF
MLRGADIVRCDNLGQWTAPAPVCQALQCQDLPVPNEARVNCSHPFGAFRYQSVCSFTCNE
GLLLVGASVLQCLATGNWNSVPPECQAIPCTPLLSPQNGTMTCVQPLGSSSYKSTCQFIC
DEGYSLSGPERLDCTRSGRWTDSPPMCEAIKCPELFAPEQGSLDCSDTRGEFNVGSTCHF
SCNNGFKLEGPNNVECTTSGRWSATPPTCKGIASLPTPGLQCPALTTPGQGTMYCRHHPG
TFGFNTTCYFGCNAGFTLIGDSTLSCRPSGQWTAVTPACRAVKCSELHVNKPIAMNCSNL
WGNFSYGSICSFHCLEGQLLNGSAQTACQENGHWSTTVPTCQAGPLTIQEALTYFGGAVA
STIGLIMGGTLLALLRKRFRQKDDGKCPLNPHSHLGTYGVFTNAAFDPSP

# Drug_Target_10_Reaction:
Not Available

# Drug_Target_10_Signals:
1-41

# Drug_Target_10_Specific_Function:
Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes. Mediates the interaction of activated endothelial cells or platelets with leukocytes. The ligand recognized is sialyl-Lewis X

# Drug_Target_10_SwissProt_ID:
P16109

# Drug_Target_10_SwissProt_Name:
LYAM3_HUMAN

# Drug_Target_10_Synonyms:
CD62P antigen
GMP-140
Granule membrane protein 140
LECAM3
Leukocyte-endothelial cell adhesion molecule 3
P-selectin precursor
PADGEM

# Drug_Target_10_Theoretical_pI:
6.64

# Drug_Target_10_Transmembrane_Regions:
772-795

# Drug_Target_11_Cellular_Location:
Not Available

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
Not Available

# Drug_Target_11_GenBank_ID_Gene:
Not Available

# Drug_Target_11_GenBank_ID_Protein:
Not Available

# Drug_Target_11_GeneCard_ID:
Not Available

# Drug_Target_11_Gene_Name:
MBL2

# Drug_Target_11_Gene_Sequence:
Not Available

# Drug_Target_11_General_Function:
Not Available

# Drug_Target_11_General_References:
Not Available

# Drug_Target_11_HGNC_ID:
Not Available

# Drug_Target_11_HPRD_ID:
Not Available

# Drug_Target_11_ID:
6992

# Drug_Target_11_Locus:
Not Available

# Drug_Target_11_Molecular_Weight:
Not Available

# Drug_Target_11_Name:
Mannose-binding protein C

# Drug_Target_11_Number_of_Residues:
0

# Drug_Target_11_PDB_ID:
Not Available

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
Not Available

# Drug_Target_11_Protein_Sequence:
Not Available

# Drug_Target_11_Reaction:
Not Available

# Drug_Target_11_Signals:
Not Available

# Drug_Target_11_Specific_Function:
Not Available

# Drug_Target_11_SwissProt_ID:
P11226

# Drug_Target_11_SwissProt_Name:
MBL2_HUMAN

# Drug_Target_11_Synonyms:
Not Available

# Drug_Target_11_Theoretical_pI:
Not Available

# Drug_Target_11_Transmembrane_Regions:
Not Available

# Drug_Target_12_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
SELE

# Drug_Target_12_GenBank_ID_Gene:
M30640

# Drug_Target_12_GenBank_ID_Protein:
182048

# Drug_Target_12_GeneCard_ID:
SELE

# Drug_Target_12_Gene_Name:
SELE

# Drug_Target_12_Gene_Sequence:
>1833 bp
ATGATTGCTTCACAGTTTCTCTCAGCTCTCACTTTGGTGCTTCTCATTAAAGAGAGTGGA
GCCTGGTCTTACAACACCTCCACGGAAGCTATGACTTATGATGAGGCCAGTGCTTATTGT
CAGCAAAGGTACACACACCTGGTTGCAATTCAAAACAAAGAAGAGATTGAGTACCTAAAC
TCCATATTGAGCTATTCACCAAGTTATTACTGGATTGGAATCAGAAAAGTCAACAATGTG
TGGGTCTGGGTAGGAACCCAGAAACCTCTGACAGAAGAAGCCAAGAACTGGGCTCCAGGT
GAACCCAACAATAGGCAAAAAGATGAGGACTGCGTGGAGATCTACATCAAGAGAGAAAAA
GATGTGGGCATGTGGAATGATGAGAGGTGCAGCAAGAAGAAGCTTGCCCTATGCTACACA
GCTGCCTGTACCAATACATCCTGCAGTGGCCACGGTGAATGTGTAGAGACCATCAATAAT
TACACTTGCAAGTGTGACCCTGGCTTCAGTGGACTCAAGTGTGAGCAAATTGTGAACTGT
ACAGCCCTGGAATCCCCTGAGCATGGAAGCCTGGTTTGCAGTCACCCACTGGGAAACTTC
AGCTACAATTCTTCCTGCTCTATCAGCTGTGATAGGGGTTACCTGCCAAGCAGCATGGAG
ACCATGCAGTGTATGTCCTCTGGAGAATGGAGTGCTCCTATTCCAGCCTGCAATGTGGTT
GAGTGTGATGCTGTGACAAATCCAGCCAATGGGTTCGTGGAATGTTTCCAAAACCCTGGA
AGCTTCCCATGGAACACAACCTGTACATTTGACTGTGAAGAAGGATTTGAACTAATGGGA
GCCCAGAGCCTTCAGTGTACCTCATCTGGGAATTGGGACAACGAGAAGCCAACGTGTAAA
GCTGTGACATGCAGGGCCGTCCGCCAGCCTCAGAATGGCTCTGTGAGGTGCAGCCATTCC
CCTGCTGGAGAGTTCACCTTCAAATCATCCTGCAACTTCACCTGTGAGGAAGGCTTCATG
TTGCAGGGACCAGCCCAGGTTGAATGCACCACTCAAGGGCAGTGGACACAGCAAATCCCA
GTTTGTGAAGCTTTCCAGTGCACAGCCTTGTCCAACCCCGAGCGAGGCTACATGAATTGT
CTTCCTAGTGCTTCTGGCAGTTTCCGTTATGGGTCCAGCTGTGAGTTCTCCTGTGAGCAG
GGTTTTGTGTTGAAGGGATCCAAAAGGCTCCAATGTGGCCCCACAGGGGAGTGGGACAAC
GAGAAGCCCACATGTGAAGCTGTGAGATGCGATGCTGTCCACCAGCCCCCGAAGGGTTTG
GTGAGGTGTGCTCATTCCCCTATTGGAGAATTCACCTACAAGTCCTCTTGTGCCTTCAGC
TGTGAGGAGGGATTTGAATTACATGGATCAACTCAACTTGAGTGCACATCTCAGGGACAA
TGGACAGAAGAGGTTCCTTCCTGCCAAGTGGTAAAATGTTCAAGCCTGGCAGTTCCGGGA
AAGATCAACATGAGCTGCAGTGGGGAGCCCGTGTTTGGCACTGTGTGCAAGTTCGCCTGT
CCTGAAGGATGGACGCTCAATGGCTCTGCAGCTCGGACATGTGGAGCCACAGGACACTGG
TCTGGCCTGCTACCTACCTGTGAAGCTCCCACTGAGTCCAACATTCCCTTGGTAGCTGGA
CTTTCTGCTGCTGGACTCTCCCTCCTGACATTAGCACCATTTCTCCTCTGGCTTCGGAAA
TGCTTACGGAAAGCAAAGAAATTTGTTCCTGCCAGCAGCTGCCAAAGCCTTGAATCAGAT
GGAAGCTACCAAAAGCCTTCTTACATCCTTTAA

# Drug_Target_12_General_Function:
Involved in sugar binding

# Drug_Target_12_General_References:
10391210	Halushka MK, Fan JB, Bentley K, Hsie L, Shen N, Weder A, Cooper R, Lipshutz R, Chakravarti A: Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet. 1999 Jul;22(3):239-47.
10982036	Sass C, Pallaud C, Zannad F, Visvikis S: Relationship between E-selectin L/F554 polymorphism and blood pressure in the Stanislas cohort. Hum Genet. 2000 Jul;107(1):58-61.
1689848	Hession C, Osborn L, Goff D, Chi-Rosso G, Vassallo C, Pasek M, Pittack C, Tizard R, Goelz S, McCarthy K, et al.: Endothelial leukocyte adhesion molecule 1: direct expression cloning and functional interactions. Proc Natl Acad Sci U S A. 1990 Mar;87(5):1673-7.
1701274	Phillips ML, Nudelman E, Gaeta FC, Perez M, Singhal AK, Hakomori S, Paulson JC: ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex. Science. 1990 Nov 23;250(4984):1130-2.
1703529	Collins T, Williams A, Johnston GI, Kim J, Eddy R, Shows T, Gimbrone MA Jr, Bevilacqua MP: Structure and chromosomal location of the gene for endothelial-leukocyte adhesion molecule 1. J Biol Chem. 1991 Feb 5;266(4):2466-73.
2466335	Bevilacqua MP, Stengelin S, Gimbrone MA Jr, Seed B: Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science. 1989 Mar 3;243(4895):1160-5.
7509040	Graves BJ, Crowther RL, Chandran C, Rumberger JM, Li S, Huang KS, Presky DH, Familletti PC, Wolitzky BA, Burns DK: Insight into E-selectin/ligand interaction from the crystal structure and mutagenesis of the lec/EGF domains. Nature. 1994 Feb 10;367(6463):532-8.
7533025	Wenzel K, Felix S, Kleber FX, Brachold R, Menke T, Schattke S, Schulte KL, Glaser C, Rohde K, Baumann G, et al.: E-selectin polymorphism and atherosclerosis: an association study. Hum Mol Genet. 1994 Nov;3(11):1935-7.
7681016	Mills A: Modelling the carbohydrate recognition domain of human E-selectin. FEBS Lett. 1993 Mar 15;319(1-2):5-11.
8557254	Wenzel K, Ernst M, Rohde K, Baumann G, Speer A: DNA polymorphisms in adhesion molecule genes--a new risk factor for early atherosclerosis. Hum Genet. 1996 Jan;97(1):15-20.
9933738	Ye SQ, Usher D, Virgil D, Zhang LQ, Yochim SE, Gupta R: A PstI polymorphism detects the mutation of serine128 to arginine in CD 62E gene - a risk factor for coronary artery disease. J Biomed Sci. 1999 Jan;6(1):18-21.

# Drug_Target_12_HGNC_ID:
HGNC:10718

# Drug_Target_12_HPRD_ID:
00566

# Drug_Target_12_ID:
1756

# Drug_Target_12_Locus:
1q22-q25

# Drug_Target_12_Molecular_Weight:
66655

# Drug_Target_12_Name:
E-selectin

# Drug_Target_12_Number_of_Residues:
610

# Drug_Target_12_PDB_ID:
1ESL

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF00008	EGF
PF00059	Lectin_C
PF00084	Sushi

# Drug_Target_12_Protein_Sequence:
>E-selectin precursor
MIASQFLSALTLVLLIKESGAWSYNTSTEAMTYDEASAYCQQRYTHLVAIQNKEEIEYLN
SILSYSPSYYWIGIRKVNNVWVWVGTQKPLTEEAKNWAPGEPNNRQKDEDCVEIYIKREK
DVGMWNDERCSKKKLALCYTAACTNTSCSGHGECVETINNYTCKCDPGFSGLKCEQIVNC
TALESPEHGSLVCSHPLGNFSYNSSCSISCDRGYLPSSMETMQCMSSGEWSAPIPACNVV
ECDAVTNPANGFVECFQNPGSFPWNTTCTFDCEEGFELMGAQSLQCTSSGNWDNEKPTCK
AVTCRAVRQPQNGSVRCSHSPAGEFTFKSSCNFTCEEGFMLQGPAQVECTTQGQWTQQIP
VCEAFQCTALSNPERGYMNCLPSASGSFRYGSSCEFSCEQGFVLKGSKRLQCGPTGEWDN
EKPTCEAVRCDAVHQPPKGLVRCAHSPIGEFTYKSSCAFSCEEGFELHGSTQLECTSQGQ
WTEEVPSCQVVKCSSLAVPGKINMSCSGEPVFGTVCKFACPEGWTLNGSAARTCGATGHW
SGLLPTCEAPTESNIPLVAGLSAAGLSLLTLAPFLLWLRKCLRKAKKFVPASSCQSLESD
GSYQKPSYIL

# Drug_Target_12_Reaction:
Not Available

# Drug_Target_12_Signals:
1-21

# Drug_Target_12_Specific_Function:
Expressed on cytokine induced endothelial cells and mediates their binding to leukocytes. The ligand recognized by ELAM-1 is sialyl-lewis X (alpha(1->3)fucosylated derivatives of polylactosamine that are found at the nonreducing termini of glycolipids)

# Drug_Target_12_SwissProt_ID:
P16581

# Drug_Target_12_SwissProt_Name:
LYAM2_HUMAN

# Drug_Target_12_Synonyms:
CD62E antigen
E-selectin precursor
ELAM-1
Endothelial leukocyte adhesion molecule 1
LECAM2
Leukocyte-endothelial cell adhesion molecule 2

# Drug_Target_12_Theoretical_pI:
4.94

# Drug_Target_12_Transmembrane_Regions:
557-578

# Drug_Target_13_Cellular_Location:
Not Available

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
REG1A

# Drug_Target_13_GenBank_ID_Gene:
M27190

# Drug_Target_13_GenBank_ID_Protein:
623413

# Drug_Target_13_GeneCard_ID:
REG1A

# Drug_Target_13_Gene_Name:
REG1A

# Drug_Target_13_Gene_Sequence:
>501 bp
ATGGCTCAGACCAACTCGTTCTTCATGCTGATCTCCTCCCTGATGTTCCTGTCTCTGAGC
CAAGGCCAAGAGGCCCAGACAGAGTTGCCCCAGGCCCGGATCAGCTGCCCAGAAGGCACC
AATGCCTATCGCTCCTACTGCTACTACTTTAATGAAGACCGTGAGACCTGGGTTGATGCA
GATCTCTATTGCCAGAACATGAATTCGGGCAACCTGGTGTCTGTGCTCACCCAGGCCGAG
GGTGCCTTTGTGGCCTCACTGATTAAGGAGAGTGGCACTGATGACTTCAATGTCTGGATT
GGCCTCCATGACCCCAAAAAGAACCGCCGCTGGCACTGGAGCAGTGGGTCCCTGGTCTCC
TACAAGTCCTGGGGCATTGGAGCCCCAAGCAGTGTTAATCCTGGCTACTGTGTGAGCCTG
ACCTCAAGCACAGGATTCCAGAAATGGAAGGATGTGCCTTGTGAAGACAAGTTCTCCTTT
GTATGCAAGTTCAAAAACTAG

# Drug_Target_13_General_Function:
Involved in sugar binding

# Drug_Target_13_General_References:
10625646	Gerbaud V, Pignol D, Loret E, Bertrand JA, Berland Y, Fontecilla-Camps JC, Canselier JP, Gabas N, Verdier JM: Mechanism of calcite crystal growth inhibition by the N-terminal undecapeptide of lithostathine. J Biol Chem. 2000 Jan 14;275(2):1057-64.
2226837	Itoh T, Tsuzuki H, Katoh T, Teraoka H, Matsumoto K, Yoshida N, Terazono K, Watanabe T, Yonekura H, Yamamoto H, et al.: Isolation and characterization of human reg protein produced in Saccharomyces cerevisiae. FEBS Lett. 1990 Oct 15;272(1-2):85-8.
2332435	Watanabe T, Yonekura H, Terazono K, Yamamoto H, Okamoto H: Complete nucleotide sequence of human reg gene and its expression in normal and tumoral tissues. The reg protein, pancreatic stone protein, and pancreatic thread protein are one and the same product of the gene. J Biol Chem. 1990 May 5;265(13):7432-9.
2394826	de la Monte SM, Ozturk M, Wands JR: Enhanced expression of an exocrine pancreatic protein in Alzheimer's disease and the developing human brain. J Clin Invest. 1990 Sep;86(3):1004-13.
2493268	De Caro AM, Adrich Z, Fournet B, Capon C, Bonicel JJ, De Caro JD, Rovery M: N-terminal sequence extension in the glycosylated forms of human pancreatic stone protein. The 5-oxoproline N-terminal chain is O-glycosylated on the 5th amino acid residue. Biochim Biophys Acta. 1989 Feb 23;994(3):281-4.
2525567	Giorgi D, Bernard JP, Rouquier S, Iovanna J, Sarles H, Dagorn JC: Secretory pancreatic stone protein messenger RNA. Nucleotide sequence and expression in chronic calcifying pancreatitis. J Clin Invest. 1989 Jul;84(1):100-6.
2764894	Stewart TA: The human reg gene encodes pancreatic stone protein. Biochem J. 1989 Jun 1;260(2):622-3.
2963000	Terazono K, Yamamoto H, Takasawa S, Shiga K, Yonemura Y, Tochino Y, Okamoto H: A novel gene activated in regenerating islets. J Biol Chem. 1988 Feb 15;263(5):2111-4.
3108036	Rouimi P, Bonicel J, Rovery M, De Caro A: Cleavage of the Arg-Ile bond in the native polypeptide chain of human pancreatic stone protein. FEBS Lett. 1987 Jun 1;216(2):195-9.
3541906	Montalto G, Bonicel J, Multigner L, Rovery M, Sarles H, De Caro A: Partial amino acid sequence of human pancreatic stone protein, a novel pancreatic secretory protein. Biochem J. 1986 Aug 15;238(1):227-32.
3665916	De Caro AM, Bonicel JJ, Rouimi P, De Caro JD, Sarles H, Rovery M: Complete amino acid sequence of an immunoreactive form of human pancreatic stone protein isolated from pancreatic juice. Eur J Biochem. 1987 Oct 1;168(1):201-7.
3908481	Gross J, Carlson RI, Brauer AW, Margolies MN, Warshaw AL, Wands JR: Isolation, characterization, and distribution of an unusual pancreatic human secretory protein. J Clin Invest. 1985 Dec;76(6):2115-26.
8654365	Bertrand JA, Pignol D, Bernard JP, Verdier JM, Dagorn JC, Fontecilla-Camps JC: Crystal structure of human lithostathine, the pancreatic inhibitor of stone formation. EMBO J. 1996 Jun 3;15(11):2678-84.
8961348	Patard L, Stoven V, Gharib B, Bontems F, Lallemand JY, De Reggi M: What function for human lithostathine?: structural investigations by three-dimensional structure modeling and high-resolution NMR spectroscopy. Protein Eng. 1996 Nov;9(11):949-57.

# Drug_Target_13_HGNC_ID:
HGNC:9951

# Drug_Target_13_HPRD_ID:
01338

# Drug_Target_13_ID:
1130

# Drug_Target_13_Locus:
2p12

# Drug_Target_13_Molecular_Weight:
18731

# Drug_Target_13_Name:
Lithostathine 1 alpha

# Drug_Target_13_Number_of_Residues:
166

# Drug_Target_13_PDB_ID:
1LIT

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF00059	Lectin_C

# Drug_Target_13_Protein_Sequence:
>Lithostathine 1 alpha precursor
MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA
DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS
YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN

# Drug_Target_13_Reaction:
Not Available

# Drug_Target_13_Signals:
1-22

# Drug_Target_13_Specific_Function:
Might act as an inhibitor of spontaneous calcium carbonate precipitation. May be associated with neuronal sprouting in brain, and with brain and pancreas regeneration

# Drug_Target_13_SwissProt_ID:
P05451

# Drug_Target_13_SwissProt_Name:
REG1A_HUMAN

# Drug_Target_13_Synonyms:
ICRF
Islet cells regeneration factor
Islet of Langerhans regenerating protein
Lithostathine 1 alpha precursor
PSP
PTP
Pancreatic stone protein
Pancreatic thread protein
REG
Regenerating protein I alpha

# Drug_Target_13_Theoretical_pI:
5.73

# Drug_Target_13_Transmembrane_Regions:
None

# Drug_Target_14_Cellular_Location:
Not Available

# Drug_Target_14_Chromosome_Location:
Not Available

# Drug_Target_14_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
Not Available

# Drug_Target_14_GenBank_ID_Gene:
Not Available

# Drug_Target_14_GenBank_ID_Protein:
Not Available

# Drug_Target_14_GeneCard_ID:
Not Available

# Drug_Target_14_Gene_Name:
Not Available

# Drug_Target_14_Gene_Sequence:
>2763 bp
ATGTCCACGATTACACAATTCCCTTCAGGAAACACTCAGTACAGGATTGAGTTCGACTAC
CTAGCCAGAACGTTTGTTGTTGTTACGCTGGTGAATAGCTCTAACCCTACCCTGAACCGT
GTACTGGAAGTTGGTCGAGATTACCGATTCCTTAACCCAACGATGATTGAGATGTTGGTG
GACCAATCAGGTTTCGACATCGTTCGTATTCACCGTCAGACTGGGACTGACTTAGTGGTA
GACTTCAGGAATGGCTCAGTGTTGACAGCTAGTGACCTGACCACTGCAGAGCTTCAGGCT
ATCCATATTGCAGAAGAAGGTCGAGACCAAACGGTTGACTTAGCGAAGGAATATGCCGAT
GCTGCTGGTAGCTCTGCTGGCAACGCTAAGGATAGCGAGGACGAAGCACGACGAATCGCT
GAGAGTATCAGGGCAGCTGGTCTAATTGGTTATATGACCCGTCGCTCCTTCGAGAAAGGC
TACAACGTTACAACATGGAGCGAGGTCCTGCTATGGGAAGAGGATGGTGATTATTACCGC
TGGGATGGTACGCTTCCAAAGAACGTTCCTGCTGGTTCAACTCCTGAAACTTCCGGTGGG
ATTGGATTAGGTGCGTGGGTTAGTGTTGGTGATGCTGCTTTAAGAAGTCAGATTTCAAAC
CCGGAAGGGGCAATACTCTACCCTGAATTACATAGAGCACGCTGGCTTGATGAAAAAGAT
GCTCGTGGTTGGGGTGCTAAAGGGGATGGTGTCACTGATGATACAGCAGCGTTAACGAGC
GCATTAAACGACACACCGGTTGGACAAAAGATTAATGGCAATGGGAAGACATATAAGGTC
ACATCCCTGCCTGACATTAGTCGCTTCATCAACACTCGTTTCGTTTATGAGCGCATTCCC
GGACAACCTCTTTATTATGCCTCTGAAGAATTTGTTCAGGGTGAGCTATTCAAAATAACG
GACACCCCTTATTACAATGCGTGGCCTCAGGATAAAGCGTTCGTATATGAGAATGTGATA
TATGCACCTTACATGGGTAGCGATCGTCATGGTGTTAGTCGTCTGCATGTATCATGGGTT
AAGTCTGGTGATGATGGTCAAACATGGTCTACTCCAGAGTGGTTAACTGATCTGCATCCA
GATTACCCTACAGTGAACTATCATTGTATGAGTATGGGTGTATGTCGCAACCGTCTGTTT
GCCATGATTGAAACACGTACCTTAGCCAAGAACGCATTAACCAATTGTGCATTGTGGGAT
CGCCCCATGTCTCGTAGCCTGCATCTTACTGGTGGTATCACTAAAGCTGCAAATCAGCGA
TATGCAACAATACATGTACCAGACCACGGACTATTCGTGGGTGATTTTGTTAACTTCTCT
AATTCTGCGGTAACAGGTGTATCCGGTGATATGACTGTTGCAACCGTAATAGATAAGGAC
AACTTCACGGTTCTTACACCCAACCAGCAGACTTCAGATTTGAATAACGCTGGAAAGAAT
TGGCACATGGGTACTTCTTTCCATAAGTCTCCATGGCGTAAGACAGATCTTGGTCTAATC
CCTAGTGTCACAGAGGTGCATAGCTTTGCTACTATTGATAACAATGGCTTTGCTATGGGC
TATCATCAAGGTGATGTAGCTCCACGAGAAGTTGGGCTTTTCTACTTCCCTGATGCTTTC
AATAGCCCATCTAATTATGTTCGTCGTCAGATACCATCTGAGTATGAACCAGATGCGTCA
GAGCCGTGCATCAAGTACTATGACGGTGTATTATACCTTATCACTCGTGGCACTCGTGGT
GATAGACTAGGTAGCTCTTTGCATCGTAGTAGAGACATAGGTCAGACTTGGGAGTCACTG
AGATTTCCACATAATGTTCATCGTACTACATTACCTTTTGCTAAAGTAGGGGATGACCTT
ATTATGTTTGGTTCAGAACGTGCAGAAAATGAATGGGAAGCAGGTGCACCAGATGATCGT
TACAAGGCATCTTATCCTCGCACCTTCTATGCACGCTTGAATGTAAACAATTGGAATGCA
GATGATATTGAATGGGTTAACATCACTGACCAGATTTATCAGGGCGGAATAGTTAACTCA
GGTGTAGGTGTTGGTTCGGTAGTTGTGAAGGATAATTACATCTACTACATGTTTGGTGGA
GAGGACCATTTTAACCCATGGACATATGGAGATAACTCAGCGAAAGACCCATTCAAATCG
GATGGTCACCCCTCGGATTTGTATTGCTACAAAATGAAGATTGGCCCAGACAATCGTGTT
TCCAGAGATTTCAGATATGGTGCTGTACCCAACAGAGCTGTTCCCGTGTTTTTTGATACG
AATGGGGTTCGCACTGTTCCTGCGCCAATGGAATTTACAGGGGATTTGGGTTTAGGTCAT
GTGACCATTAGAGCCAGCACCAGTAGTAACATTCGCTCTGAAGTTTTAATGGAAGGTGAA
TATGGGTTTATCGGGAAATCTATACCGACTGATAACCCGGCAGGGCAGCGCATCATATTT
TGCGGGGGTGAAGGCACCAGTTCAACGACTGGCGCACAGATTACGCTATATGGTGCAAAT
AACACCGACTCAAGGCGAATAGTTTACAACGGAGATGAGCATCTATTTCAGAGTGCTGAT
GTTAAGCCTTATAACGATAACGTCACTGCGCTTGGTGGGCCTAGCAACCGTTTCACCACT
GCATACCTCGGAAGCAACCCTATTGTTACTTCTAACGGGGGAGGAGGAAAACAGAGCCGG
TAG

# Drug_Target_14_General_Function:
Involved in endo-alpha-sialidase activity

# Drug_Target_14_General_References:
8331067	Petter JG, Vimr ER: Complete nucleotide sequence of the bacteriophage K1F tail gene encoding endo-N-acylneuraminidase (endo-N) and comparison to an endo-N homolog in bacteriophage PK1E. J Bacteriol. 1993 Jul;175(14):4354-63.

# Drug_Target_14_HGNC_ID:
Not Available

# Drug_Target_14_HPRD_ID:
Not Available

# Drug_Target_14_ID:
3629

# Drug_Target_14_Locus:
Not Available

# Drug_Target_14_Molecular_Weight:
102014

# Drug_Target_14_Name:
Endo-N-acetylneuraminidase

# Drug_Target_14_Number_of_Residues:
920

# Drug_Target_14_PDB_ID:
1V0F

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
PF02012	BNR
PF03906	Phage_T7_tail

# Drug_Target_14_Protein_Sequence:
>Endo-N-acetylneuraminidase
MSTITQFPSGNTQYRIEFDYLARTFVVVTLVNSSNPTLNRVLEVGRDYRFLNPTMIEMLV
DQSGFDIVRIHRQTGTDLVVDFRNGSVLTASDLTTAELQAIHIAEEGRDQTVDLAKEYAD
AAGSSAGNAKDSEDEARRIAESIRAAGLIGYMTRRSFEKGYNVTTWSEVLLWEEDGDYYR
WDGTLPKNVPAGSTPETSGGIGLGAWVSVGDAALRSQISNPEGAILYPELHRARWLDEKD
ARGWGAKGDGVTDDTAALTSALNDTPVGQKINGNGKTYKVTSLPDISRFINTRFVYERIP
GQPLYYASEEFVQGELFKITDTPYYNAWPQDKAFVYENVIYAPYMGSDRHGVSRLHVSWV
KSGDDGQTWSTPEWLTDLHPDYPTVNYHCMSMGVCRNRLFAMIETRTLAKNALTNCALWD
RPMSRSLHLTGGITKAANQRYATIHVPDHGLFVGDFVNFSNSAVTGVSGDMTVATVIDKD
NFTVLTPNQQTSDLNNAGKNWHMGTSFHKSPWRKTDLGLIPSVTEVHSFATIDNNGFAMG
YHQGDVAPREVGLFYFPDAFNSPSNYVRRQIPSEYEPDASEPCIKYYDGVLYLITRGTRG
DRLGSSLHRSRDIGQTWESLRFPHNVHRTTLPFAKVGDDLIMFGSERAENEWEAGAPDDR
YKASYPRTFYARLNVNNWNADDIEWVNITDQIYQGGIVNSGVGVGSVVVKDNYIYYMFGG
EDHFNPWTYGDNSAKDPFKSDGHPSDLYCYKMKIGPDNRVSRDFRYGAVPNRAVPVFFDT
NGVRTVPAPMEFTGDLGLGHVTIRASTSSNIRSEVLMEGEYGFIGKSIPTDNPAGQRIIF
CGGEGTSSTTGAQITLYGANNTDSRRIVYNGDEHLFQSADVKPYNDNVTALGGPSNRFTT
AYLGSNPIVTSNGGGGKQSR

# Drug_Target_14_Reaction:
Endohydrolysis of (2->8)-alpha-sialosyl linkages in oligo- or poly(sialic) acids

# Drug_Target_14_Signals:
None

# Drug_Target_14_Specific_Function:
Responsible for initial absorption of the phage to the host bacterium. Degradation of the alpha-2,8-linked polysialic acid K1 capsule

# Drug_Target_14_SwissProt_ID:
Q04830

# Drug_Target_14_SwissProt_Name:
ENAN_BPK1F

# Drug_Target_14_Synonyms:
EC 3.2.1.129
Endo-N
Endosialidase
G102

# Drug_Target_14_Theoretical_pI:
5.37

# Drug_Target_14_Transmembrane_Regions:
None

# Drug_Target_15_Cellular_Location:
Secreted protein

# Drug_Target_15_Chromosome_Location:
Not Available

# Drug_Target_15_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_15_Essentiality:
Non-Essential

# Drug_Target_15_GenAtlas_ID:
Not Available

# Drug_Target_15_GenBank_ID_Gene:
M11118

# Drug_Target_15_GenBank_ID_Protein:
153000

# Drug_Target_15_GeneCard_ID:
Not Available

# Drug_Target_15_Gene_Name:
entB

# Drug_Target_15_Gene_Sequence:
>801 bp
ATGTATAAGAGATTATTTATTTCACATGTAATTTTGATATTCGCACTGATATTAGTTATT
TCTACACCCAACGTTTTAGCAGAGAGTCAACCAGATCCTAAACCAGATGAGTTGCACAAA
TCGAGTAAATTCACTGGTTTGATGGAAAATATGAAAGTTTTGTATGATGATAATCATGTA
TCAGCAATAAACGTTAAATCTATAGATCAATTTCTATACTTTGACTTAATATATTCTATT
AAGGACACTAAGTTAGGGAATTATGATAATGTTCGAGTCGAATTTAAAAACAAAGATTTA
GCTGATAAATACAAAGATAAATACGTAGATGTGTTTGGAGCTAATTATTATTATCAATGT
TATTTTTCTAAAAAAACGAATGATATTAATTCGCATCAAACTGACAAACGAAAAACTTGT
ATGTATGGTGGTGTAACTGAGCATAATGGAAACCAATTAGATAAATATAGAAGTATTACT
GTTCGGGTATTTGAAGATGGTAAAAATTTATTATCTTTTGACGTACAAACTAATAAGAAA
AAGGTGACTGCTCAAGAATTAGATTACCTAACTCGTCACTATTTGGTGAAAAATAAAAAA
CTCTATGAATTTAACAACTCGCCTTATGAAACGGGATATATTAAATTTATAGAAAATGAG
AATAGCTTTTGGTATGACATGATGCCTGCACCAGGAGATAAATTTGACCAATCTAAATAT
TTAATGATGTACAATGACAATAAAATGGTTGATTCTAAAGATGTGAAGATTGAAGTTTAT
CTTACGACAAAGAAAAAGTGA

# Drug_Target_15_General_Function:
Not Available

# Drug_Target_15_General_References:
1436058	Swaminathan S, Furey W, Pletcher J, Sax M: Crystal structure of staphylococcal enterotoxin B, a superantigen. Nature. 1992 Oct 29;359(6398):801-6.
3898073	Ranelli DM, Jones CL, Johns MB, Mussey GJ, Khan SA: Molecular cloning of staphylococcal enterotoxin B gene in Escherichia coli and Staphylococcus aureus. Proc Natl Acad Sci U S A. 1985 Sep;82(17):5850-4.
3957869	Jones CL, Khan SA: Nucleotide sequence of the enterotoxin B gene from Staphylococcus aureus. J Bacteriol. 1986 Apr;166(1):29-33.
5470821	Huang IY, Bergdoll MS: The primary structure of staphylococcal enterotoxin B. 3. The cyanogen bromide peptides of reduced and aminoethylated enterotoxin B, and the complete amino acid sequence. J Biol Chem. 1970 Jul 25;245(14):3518-25.
8152483	Jardetzky TS, Brown JH, Gorga JC, Stern LJ, Urban RG, Chi YI, Stauffacher C, Strominger JL, Wiley DC: Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature. 1994 Apr 21;368(6473):711-8.
9514739	Papageorgiou AC, Tranter HS, Acharya KR: Crystal structure of microbial superantigen staphylococcal enterotoxin B at 1.5 A resolution: implications for superantigen recognition by MHC class II molecules and T-cell receptors. J Mol Biol. 1998 Mar 20;277(1):61-79.
9881971	Li H, Llera A, Tsuchiya D, Leder L, Ysern X, Schlievert PM, Karjalainen K, Mariuzza RA: Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B. Immunity. 1998 Dec;9(6):807-16.

# Drug_Target_15_HGNC_ID:
Not Available

# Drug_Target_15_HPRD_ID:
Not Available

# Drug_Target_15_ID:
3547

# Drug_Target_15_Locus:
Not Available

# Drug_Target_15_Molecular_Weight:
31436

# Drug_Target_15_Name:
Enterotoxin type B

# Drug_Target_15_Number_of_Residues:
266

# Drug_Target_15_PDB_ID:
1D5M

# Drug_Target_15_Pathway:
Not Available

# Drug_Target_15_Pfam_Domain_Function:
PF01123	Stap_Strp_toxin
PF02876	Stap_Strp_tox_C

# Drug_Target_15_Protein_Sequence:
>Enterotoxin type B precursor
MYKRLFISHVILIFALILVISTPNVLAESQPDPKPDELHKSSKFTGLMENMKVLYDDNHV
SAINVKSIDQFLYFDLIYSIKDTKLGNYDNVRVEFKNKDLADKYKDKYVDVFGANYYYQC
YFSKKTNDINSHQTDKRKTCMYGGVTEHNGNQLDKYRSITVRVFEDGKNLLSFDVQTNKK
KVTAQELDYLTRHYLVKNKKLYEFNNSPYETGYIKFIENENSFWYDMMPAPGDKFDQSKY
LMMYNDNKMVDSKDVKIEVYLTTKKK

# Drug_Target_15_Reaction:
Not Available

# Drug_Target_15_Signals:
1-27

# Drug_Target_15_Specific_Function:
Staphylococcal enterotoxins cause the intoxication staphylococcal food poisoning syndrome. The illness characterized by high fever, hypotension, diarrhea, shock, and in some cases death

# Drug_Target_15_SwissProt_ID:
P01552

# Drug_Target_15_SwissProt_Name:
ETXB_STAAU

# Drug_Target_15_Synonyms:
Enterotoxin type B precursor
SEB

# Drug_Target_15_Theoretical_pI:
8.94

# Drug_Target_15_Transmembrane_Regions:
None

# Drug_Target_16_Cellular_Location:
Virion
apical cell membrane
single-pass type II membrane protein (
virion membrane. Cell membrane

# Drug_Target_16_Chromosome_Location:
Not Available

# Drug_Target_16_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_16_Essentiality:
Non-Essential

# Drug_Target_16_GenAtlas_ID:
Not Available

# Drug_Target_16_GenBank_ID_Gene:
M11445

# Drug_Target_16_GenBank_ID_Protein:
324416

# Drug_Target_16_GeneCard_ID:
Not Available

# Drug_Target_16_Gene_Name:
NA

# Drug_Target_16_Gene_Sequence:
>1413 bp
ATGAATCCAAATCAGAAGATTCTATGCACTTCTGCCACTGCTCTCGTAATAGGCACAATT
GCAGTACTCATAGGAATAACGAACTTAGGATTGAACATAGGACTACATCTGAAACCGAGC
TGCAATTGCTCACACTCACAACCCGAAGCAACCAATGCAAGCCAAACAATAATAAATAAC
TATTATAATGACACAAACATCACCCAGATAAGTAATACCAACATTCAGGTAGAGGAAAGG
GCAATTAGAGATTTCAATAACTTGACCAAAGGGCTCTGTACTATAAATTCATGGCACATA
TATGGGAAAGACAATGCGGTGAGAATTGGGGAGGACTCAGATGTTTTAGTCACAAGAGAA
CCCTATGTCTCCTGTGACCCAGATGAGTGCAGGTTCTATGCTCTCAGCCAAGGGACAACA
ATCAGAGGAAAACACTCAAATGGAACAATACACGATAGGTCTCAATATCGTGCCCTGATA
AGCTGGCCATTGTCATCACCGCCCACAGTATACAACAGCAGAGTGGAATGCATTGGATGG
TCAAGTACTAGTTGTCATGATGGCAAAACCAGGATGTCAATATGCATATCAGGCCCGAAC
AATAACGCATCAGCAGTGATCTGGTACAATAGAAGGCCTGTGACAGAAATCAACACATGG
GCCCGAAACATACTAAGGACACAAGAATCTGAATGCGTATGCCACAACGGTGTCTGCCCG
GTAGTGTTCACAGATGGGTCTGCCACTGGACCTGCAGAAACAAGAATATACTATTTTAAA
GAAGGGAAGATCTTAAAATGGGAACCTCTGGCTGGAACTGCTAAGCATATCGAAGAATGC
TCATGCTACGGAGAGCGAGCAGAGATTACTTGCACGTGTAGGGATAATTGGCAAGGCTCA
AATAGACCAGTAATTCGGATAGATCCAGTGGCGATGACACATACTAGTCAGTATATATGT
AGCCCTGTTCTCACAGATAACCCCCGACCGAATGACCCAACTGTAGGTAAGTGTAACGAC
CCTTATCCAGGCAATAACAACAATGGGGTCAAAGGGTTTTCATATCTGGATGGAGTTAAT
ACTTGGCTAGGGAGGACAATAAGCATAGCTTCAAGATCCGGATATGAGATGCTAAAGGTG
CCAAATGCATTGACAGACGATAAGTCAAAGCCCACTCAAGGTCAGACAATCGTCTTAAAC
ACTGACTGGAGTGGTTACAGTGGGTCCTTCATGGACTATTGGGCTGAGGGGGAATGCTAC
CGAGCGTGTTTTTACGTGGAGTTAATACGTGGGAGACCTAAGGAGGATAAAGTGTGGTGG
ACCAGTAATAGTATAGTATCGATGTGTTCCAGCACAGAATTCCTTGGACAATGGGACTGG
CCTGATGGGGCTAAAATAGAGTACTTCCTCTAA

# Drug_Target_16_General_Function:
Not Available

# Drug_Target_16_General_References:
3447170	Baker AT, Varghese JN, Laver WG, Air GM, Colman PM: Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus. Proteins. 1987;2(2):111-7.
3660585	Air GM, Webster RG, Colman PM, Laver WG: Distribution of sequence differences in influenza N9 neuraminidase of tern and whale viruses and crystallization of the whale neuraminidase complexed with antibodies. Virology. 1987 Oct;160(2):346-54.
4013081	Air GM, Ritchie LR, Laver WG, Colman PM: Gene and protein sequence of an influenza neuraminidase with hemagglutinin activity. Virology. 1985 Aug;145(1):117-22.
8371267	Bossart-Whitaker P, Carson M, Babu YS, Smith CD, Laver WG, Air GM: Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid. J Mol Biol. 1993 Aug 20;232(4):1069-83.
9342319	Varghese JN, Colman PM, van Donkelaar A, Blick TJ, Sahasrabudhe A, McKimm-Breschkin JL: Structural evidence for a second sialic acid binding site in avian influenza virus neuraminidases. Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):11808-12.

# Drug_Target_16_HGNC_ID:
Not Available

# Drug_Target_16_HPRD_ID:
Not Available

# Drug_Target_16_ID:
3026

# Drug_Target_16_Locus:
Not Available

# Drug_Target_16_Molecular_Weight:
52469

# Drug_Target_16_Name:
Neuraminidase

# Drug_Target_16_Number_of_Residues:
470

# Drug_Target_16_PDB_ID:
1NMB

# Drug_Target_16_Pathway:
Not Available

# Drug_Target_16_Pfam_Domain_Function:
PF00064	Neur

# Drug_Target_16_Protein_Sequence:
>Neuraminidase
MNPNQKILCTSATALVIGTIAVLIGITNLGLNIGLHLKPSCNCSHSQPEATNASQTIINN
YYNDTNITQISNTNIQVEERAIRDFNNLTKGLCTINSWHIYGKDNAVRIGEDSDVLVTRE
PYVSCDPDECRFYALSQGTTIRGKHSNGTIHDRSQYRALISWPLSSPPTVYNSRVECIGW
SSTSCHDGKTRMSICISGPNNNASAVIWYNRRPVTEINTWARNILRTQESECVCHNGVCP
VVFTDGSATGPAETRIYYFKEGKILKWEPLAGTAKHIEECSCYGERAEITCTCRDNWQGS
NRPVIRIDPVAMTHTSQYICSPVLTDNPRPNDPTVGKCNDPYPGNNNNGVKGFSYLDGVN
TWLGRTISIASRSGYEMLKVPNALTDDKSKPTQGQTIVLNTDWSGYSGSFMDYWAEGECY
RACFYVELIRGRPKEDKVWWTSNSIVSMCSSTEFLGQWDWPDGAKIEYFL

# Drug_Target_16_Reaction:
Hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)- glycosidic linkages of terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates ALL_REAC (other) R03491 R04018 R04634 R04650 R05115 R05117 R05996(G) R05998(G) R05999(G) R06012(G) R06147(G) R06253(G) INHIBITOR 2-Deoxy-2,3-dehydro-N-acetylneuraminic acid

# Drug_Target_16_Signals:
None

# Drug_Target_16_Specific_Function:
Catalyzes the removal of terminal sialic acid residues from viral and cellular glycoconjugates. Cleaves off the terminal sialic acids on the glycosylated HA during virus budding to facilitate virus release. Additionally helps virus spread through the circulation by further removing sialic acids from the cell surface. These cleavages prevent self-aggregation and ensure the efficient spread of the progeny virus from cell to cell. Otherwise, infection would be limited to one round of replication. Described as a receptor-destroying enzyme because it cleaves a terminal sialic acid from the cellular receptors. May facilitate viral invasion of the upper airways by cleaving the sialic acid moities on the mucin of the airway epithelial cells. Likely to plays a role in the budding process through its association with lipid rafts during intracellular transport. May additionally display a raft-association independent effect on budding. Plays a role in the determination of host range restriction on replication and virulence. Sialidase activity in late endosome/lysosome traffic seems to enhance virus replication

# Drug_Target_16_SwissProt_ID:
P03472

# Drug_Target_16_SwissProt_Name:
NRAM_I75A5

# Drug_Target_16_Synonyms:
EC 3.2.1.18

# Drug_Target_16_Theoretical_pI:
6.57

# Drug_Target_16_Transmembrane_Regions:
7-35

# Drug_Target_17_Cellular_Location:
Membrane
single-pass type II membrane protein

# Drug_Target_17_Chromosome_Location:
Not Available

# Drug_Target_17_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_17_Essentiality:
Non-Essential

# Drug_Target_17_GenAtlas_ID:
Not Available

# Drug_Target_17_GenBank_ID_Gene:
X04355

# Drug_Target_17_GenBank_ID_Protein:
60936

# Drug_Target_17_GeneCard_ID:
Not Available

# Drug_Target_17_Gene_Name:
HN

# Drug_Target_17_Gene_Sequence:
>1734 bp
ATGGACCGCGCAGTTAGCCAAGTTGCGTTAGAGAATGATGAAAGAGAGGCAAAAAATACA
TGGCGCTTGATATTCCGGATTGCAATCTTACTCTTAACAGTAGTGACCTTAGCTACATCT
GTAGCCTCCCTTGTATATAGCATGGGGGCTAGCACACCTAGCGACCTTGTAGGCATACCG
ACCAGGATTTCTAGGGCAGAAGAAAAGATTACATCTGCACTTGGTTCCAATCAAGATGTA
GTAGATAGGATATATAAGCAAGTGGCCCTTGAGTCTCCGTTGGCATTGTTAAACACTGAG
ACCACAATTATGAACGCAATAACATCTCTCTCTTATCAGATTAATGGAGCTGCGAACAAC
AGCGGGTGGGGGGCACCTATCCATGACCCAGATTTTATCGGGGGGATAGGCAAAGAACTC
ATTGTAGATGATGCTAGTGATGTCACATCATTCTATCCCTCTGCATTTCAAGAACATCTG
AATTTTATCCCGGCGCCTACTACAGGATCAGGTTGCACTCGGATACCTTCATTTGACATG
AGTGCTACCCATTACTGCTACACTCATAATGTAATATTGTCTGGATGCAGAGATCACTCA
CACTCACATCAGTATTTAGCACTTGGTGTGCTCCGGACAACTGCAACAGGGAGGATATTC
TTTTCTACTCTGCGTTCCATCAGTCTGGATGACACCCAAAATCGGAAGTCTTGCAGTGTG
AGTGCAACTCCCTTAGGTTGTGATATGCTGTGCTCGAAAGTCACGGAGACAGAGGAAGAA
GATTATAACTCAGCTGTCCCTACGCTGATGGCACATGGGAGGTTAGGGTTCGACGGCCAA
TACCACGAAAAGGACCTAGACGTCACAACATTATTTGAGGACTGGGTGGCCAACTACCCA
GGAGTAGGGGGTGGATCTTTTATTGACGGCCGCGTATGGTTCTCAGTCTACGGAGGGCTG
AAACCCAATTCACCCAGTGACACTGTACAGGAAGGGAAATATGTAATATACAAGCGATAC
AATGACACATGCCCAGATGAGCAAGACTACCAGATCCGAATGGCCAAGTCTTCGTATAAG
CCCGGGCGGTTTGGTGGGAAACGCATACAGCAGGCTATCTTATCTATCAAGGTGTCAACA
TCTTTGGGCGAAGACCCAGTACTGACTGTACCGCCCAACACAGTCACACTCATGGGGGCC
GAAGGCAGAATTCTCACAGTAGGGACATCTCATTTCTTGTATCAGCGAGGGTCATCATAC
TTCTCTCCCGCGTTATTATATCCTATGACAGTCAGCAACAAAACAGCCACTCTTCATAGT
CCCTATACATTCAATGCCTTCACTCGGCCAGGTAGTATCCCTTGCCAGGCTTCAGCAAGA
TGCCCCAACTCGTGTGTTACTGGAGTCTATACAGATCCATATCCCCTAATCTTCTATAGG
AACCACACCTTGCGAGGGGTATTCGGGACAATGCTTGATAGTGAACAAGCAAGACTTAAT
CCTACGTCTGCAGTATTCGATAGCACATCCCGCAGTCGCATAACTCGAGTGAGTTCAAGC
AGCACCAAAGCAGCATACACAACATCAACTTGTTTTAAAGTTGTCAAGACCAATAAGACC
TATTGTCTCAGCATTGCTGAAATATCTAATACTCTCTTCGGAGAATTCAGAATCGTCCCG
TTACTAGTTGAGATCCTCAAAAATGATGGGGTTAGAGAAGCCAGGTCTGGTTAG

# Drug_Target_17_General_Function:
Not Available

# Drug_Target_17_General_References:
2705297	Sakaguchi T, Toyoda T, Gotoh B, Inocencio NM, Kuma K, Miyata T, Nagai Y: Newcastle disease virus evolution. I. Multiple lineages defined by sequence variability of the hemagglutinin-neuraminidase gene. Virology. 1989 Apr;169(2):260-72.
3018130	Millar NS, Chambers P, Emmerson PT: Nucleotide sequence analysis of the haemagglutinin-neuraminidase gene of Newcastle disease virus. J Gen Virol. 1986 Sep;67 ( Pt 9):1917-27.

# Drug_Target_17_HGNC_ID:
Not Available

# Drug_Target_17_HPRD_ID:
Not Available

# Drug_Target_17_ID:
3609

# Drug_Target_17_Locus:
Not Available

# Drug_Target_17_Molecular_Weight:
63143

# Drug_Target_17_Name:
Hemagglutinin-neuraminidase

# Drug_Target_17_Number_of_Residues:
577

# Drug_Target_17_PDB_ID:
1USR

# Drug_Target_17_Pathway:
Not Available

# Drug_Target_17_Pfam_Domain_Function:
PF00423	HN

# Drug_Target_17_Protein_Sequence:
>Hemagglutinin-neuraminidase
MDRAVSQVALENDEREAKNTWRLIFRIAILLLTVVTLATSVASLVYSMGASTPSDLVGIP
TRISRAEEKITSALGSNQDVVDRIYKQVALESPLALLNTETTIMNAITSLSYQINGAANN
SGWGAPIHDPDFIGGIGKELIVDDASDVTSFYPSAFQEHLNFIPAPTTGSGCTRIPSFDM
SATHYCYTHNVILSGCRDHSHSHQYLALGVLRTTATGRIFFSTLRSISLDDTQNRKSCSV
SATPLGCDMLCSKVTETEEEDYNSAVPTLMAHGRLGFDGQYHEKDLDVTTLFEDWVANYP
GVGGGSFIDGRVWFSVYGGLKPNSPSDTVQEGKYVIYKRYNDTCPDEQDYQIRMAKSSYK
PGRFGGKRIQQAILSIKVSTSLGEDPVLTVPPNTVTLMGAEGRILTVGTSHFLYQRGSSY
FSPALLYPMTVSNKTATLHSPYTFNAFTRPGSIPCQASARCPNSCVTGVYTDPYPLIFYR
NHTLRGVFGTMLDSEQARLNPTSAVFDSTSRSRITRVSSSSTKAAYTTSTCFKVVKTNKT
YCLSIAEISNTLFGEFRIVPLLVEILKNDGVREARSG

# Drug_Target_17_Reaction:
Hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)- glycosidic linkages of terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates ALL_REAC (other) R03491 R04018 R04634 R04650 R05115 R05117 R05996(G) R05998(G) R05999(G) R06012(G) R06147(G) R06253(G) INHIBITOR 2-Deoxy-2,3-dehydro-N-acetylneuraminic acid

# Drug_Target_17_Signals:
None

# Drug_Target_17_Specific_Function:
Neuraminidase activity ensures the efficient spread of the virus by dissociating the mature virions from the neuraminic acid containing glycoproteins

# Drug_Target_17_SwissProt_ID:
P32884

# Drug_Target_17_SwissProt_Name:
HN_NDVB

# Drug_Target_17_Synonyms:
EC 3.2.1.18

# Drug_Target_17_Theoretical_pI:
7.09

# Drug_Target_17_Transmembrane_Regions:
27-48

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
Not Available

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X94485

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
L5

# Drug_Target_1_Gene_Sequence:
>1098 bp
ATGTCAAAGAGGCTCCGGGTGGAAGATGACTTCAACCCCGTCTACCCCTATGGCTACGCG
CGGAATCAGAATATCCCCTTCCTCACTCCCCCCTTTGTCTCCTCCGATGGATTCAAAAAC
TTCCCCCCTGGGGTACTGTCACTCAAACTGGCTGATCCAATCACCATTACCAATGGGGAT
GTATCCCTCAAGGTGGGAGGTGGTCTCACTTTGCAAGATGGAAGCCTAACTGTAAACCCT
AAGGCTCCACTGCAAGTTACTACTGATAAAAAACTTGAGCTTGCATATGATAATCCATTT
GAATGTAGTGCTAATAAATTTAGTTTAAAAGTAGGACATGGATTAAAAGTATTAGATGAA
AAAAGTGCTGCGGGGTTAAAAGATTTAATTGGCAAACTTGTGGTTTTAACAGGAAAAGGA
ATAGGCACTGAAAATTTAGAAAATACAGATGGTAGCAGCAGAGGAATTGGTATAAATGTA
AGAGCAAGAGAAGGGTTGACATTTGACAATGATGGATACTTGGTAGCATGGAACCCAAAG
TATGACACGCGCACACTTTGGACAACACCAGACACATCTCCAAACTGCACAATTGCTCAG
GATAAGGACTCTAAACTCACTTTGGTACTTACAAAGTGTGGAAGTCAAATATTAGCTAAT
GTGTCTTTGATTGTGGTCGCAGGAAAGTACCACATCATAAATAATAAGACAAATCCAGAA
ATAAAAAGTTTTACTATTAAACTGTTATTTAATAAGAACGGAGTGCTTTTAGACAACTCA
AATCTTGGAAAAGCTTATTGGAACTTTAGAAGTGGAAATTCCAATGTTTCGACAGCTTAT
GAAAAAGCAATTGGTTTTATGCCTAATTTAGTAGCGTATCCAAAACCCAGTAATTCTAAA
AAATATGCAAGAGACATAGTTTATGGAACTATATATCTTGGTGGAAAACCTGATCAGCCA
GCAGTCATTAAAACTACCTTTAACCAAGAAACTGGATGTGAATACTCTATCACATTTGAC
TTTAGTTGGTCCAAAACCTATGAAAATGTTGAATTTGAAACCACCTCTTTTACCTTCTCC
TATATTGCCCAAGAATGA

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
9007080	Arnberg N, Mei Y, Wadell G: Fiber genes of adenoviruses with tropism for the eye and the genital tract. Virology. 1997 Jan 6;227(1):239-44.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
5414

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
40132

# Drug_Target_1_Name:
Fiber protein

# Drug_Target_1_Number_of_Residues:
365

# Drug_Target_1_PDB_ID:
1UXB

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00541	Adeno_knob
PF00608	Adeno_shaft

# Drug_Target_1_Protein_Sequence:
>Fiber protein
MSKRLRVEDDFNPVYPYGYARNQNIPFLTPPFVSSDGFKNFPPGVLSLKLADPITITNGD
VSLKVGGGLTLQDGSLTVNPKAPLQVTTDKKLELAYDNPFECSANKFSLKVGHGLKVLDE
KSAAGLKDLIGKLVVLTGKGIGTENLENTDGSSRGIGINVRAREGLTFDNDGYLVAWNPK
YDTRTLWTTPDTSPNCTIAQDKDSKLTLVLTKCGSQILANVSLIVVAGKYHIINNKTNPE
IKSFTIKLLFNKNGVLLDNSNLGKAYWNFRSGNSNVSTAYEKAIGFMPNLVAYPKPSNSK
KYARDIVYGTIYLGGKPDQPAVIKTTFNQETGCEYSITFDFSWSKTYENVEFETTSFTFS
YIAQE

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q64822

# Drug_Target_1_SwissProt_Name:
Q64822_9ADEN

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
8.73

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Not Available

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
SIGLEC1

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
Not Available

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
7102

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
Not Available

# Drug_Target_2_Name:
Sialoadhesin

# Drug_Target_2_Number_of_Residues:
0

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
Not Available

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
Not Available

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
Q9BZZ2

# Drug_Target_2_SwissProt_Name:
SN_HUMAN

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
Not Available

# Drug_Target_2_Transmembrane_Regions:
Not Available

# Drug_Target_3_Cellular_Location:
Secreted protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
Not Available

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
AZGP1

# Drug_Target_3_GenBank_ID_Gene:
D90427

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
AZGP1

# Drug_Target_3_Gene_Sequence:
>888 bp
ATGGTGCCTGTCCTGCTGTCTCTGCTGCTGCTTCTGGGTCCTGCTGTCCCCCAGGAGAAC
CAAGATGGTCGTTACTCTCTGACCTATATCTACACTGGGCTGTCCAAGCATGTTGAAGAC
GTCCCCGCGTTTCAGGCCCTTGGCTCACTCAATGACCTCCAGTTCTTTAGATACAACAGT
AAAGACAGGAAGTCTCAGCCCATGGGACTCTGGAGACAGGTGGAAGGAATGGAGGATTGG
AAGCAGGACAGCCAACTTCAGAAGGCCAGGGAGGACATCTTTATGGAGACCCTGAAAGAC
ATTGTGGAGTATTACAACGACAGTAACGGGTCTCACGTATTGCAGGGAAGGTTTGGTTGT
GAGATCGAGAATAACAGAAGCAGCGGAGCATTCTGGAAATATTACTATGATGGAAAGGAC
TACATTGAATTCAACAAAGAAATCCCAGCCTGGGTCCCCTTCGACCCAGCAGCCCAGATA
ACCAAGCAGAAGTGGGAGGCAGAACCAGTCTACGTGCAGCGGGCCAAGGCTTACCTGGAG
GAGGAGTGCCCTGCGACTCTGCGGAAATACCTGAAATACAGCAAAAATATCCTGGACCGG
CAAGATCCTCCCTCTGTGGTGGTCACCAGCCACCAGGCCCCAGGAGAAAAGAAGAAACTG
AAGTGCCTGGCCTACGACTTCTACCCAGGGAAAATTGATGTGCACTGGACTCGGGCCGGC
GAGGTGCAGGAGCCTGAGTTACGGGGAGATGTTCTTCACAATGGAAATGGCACTTACCAG
TCCTGGGTGGTGGTGGCAGTGCCCCCGCAGGACACAGCCCCCTACTCCTGCCACGTGCAG
CACAGCAGCCTGGCCCAGCCCCTCGTGGTGCCCTGGGAGGCCAGCTAG

# Drug_Target_3_General_Function:
Not Available

# Drug_Target_3_General_References:
11425849	Kennedy MW, Heikema AP, Cooper A, Bjorkman PJ, Sanchez LM: Hydrophobic ligand binding by Zn-alpha 2-glycoprotein, a soluble fat-depleting factor related to major histocompatibility complex proteins. J Biol Chem. 2001 Sep 14;276(37):35008-13. Epub 2001 Jun 25.
12853948	Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7. Nature. 2003 Jul 10;424(6945):157-64.
1915885	Freije JP, Fueyo A, Uria J, Lopez-Otin C: Human Zn-alpha 2-glycoprotein cDNA cloning and expression analysis in benign and malignant breast tissues. FEBS Lett. 1991 Sep 23;290(1-2):247-9.
2049092	Ueyama H, Niwa M, Tada T, Sasaki M, Ohkubo I: Cloning and nucleotide sequence of a human Zn-alpha 2-glycoprotein cDNA and chromosomal assignment of its gene. Biochem Biophys Res Commun. 1991 Jun 14;177(2):696-703.
3422450	Araki T, Gejyo F, Takagaki K, Haupt H, Schwick HG, Burgi W, Marti T, Schaller J, Rickli E, Brossmer R, et al.: Complete amino acid sequence of human plasma Zn-alpha 2-glycoprotein and its homology to histocompatibility antigens. Proc Natl Acad Sci U S A. 1988 Feb;85(3):679-83.
8241150	Ueyama H, Deng HX, Ohkubo I: Molecular cloning and chromosomal assignment of the gene for human Zn-alpha 2-glycoprotein. Biochemistry. 1993 Dec 7;32(48):12968-76.
8307568	Freije JP, Fueyo A, Uria JA, Velasco G, Sanchez LM, Lopez-Boado YS, Lopez-Otin C: Human Zn-alpha 2-glycoprotein: complete genomic sequence, identification of a related pseudogene and relationship to class I major histocompatibility complex genes. Genomics. 1993 Dec;18(3):575-87.
9114041	Sanchez LM, Lopez-Otin C, Bjorkman PJ: Biochemical characterization and crystalization of human Zn-alpha2-glycoprotein, a soluble class I major histocompatibility complex homolog. Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4626-30.

# Drug_Target_3_HGNC_ID:
HGNC:910

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
4857

# Drug_Target_3_Locus:
7q22.1

# Drug_Target_3_Molecular_Weight:
33872

# Drug_Target_3_Name:
Zinc-alpha-2-glycoprotein

# Drug_Target_3_Number_of_Residues:
295

# Drug_Target_3_PDB_ID:
1T80

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00129	MHC_I
PF07654	C1-set

# Drug_Target_3_Protein_Sequence:
>Zinc-alpha-2-glycoprotein
MVPVLLSLLLLLGPAVPQENQDGRYSLTYIYTGLSKHVEDVPAFQALGSLNDLQFFRYNS
KDRKSQPMGLWRQVEGMEDWKQDSQLQKAREDIFMETLKDIVEYYNDSNGSHVLQGRFGC
EIENNRSSGAFWKYYYDGKDYIEFNKEIPAWVPFDPAAQITKQKWEAEPVYVQRAKAYLE
EECPATLRKYLKYSKNILDRQDPPSVVVTSHQAPGEKKKLKCLAYDFYPGKIDVHWTRAG
EVQEPELRGDVLHNGNGTYQSWVVVAVPPQDTAPYSCHVQHSSLAQPLVVPWEAS

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
1-17

# Drug_Target_3_Specific_Function:
Stimulates lipid degradation in adipocytes and causes the extensive fat losses associated with some advanced cancers. May bind polyunsaturated fatty acids

# Drug_Target_3_SwissProt_ID:
P25311

# Drug_Target_3_SwissProt_Name:
ZA2G_HUMAN

# Drug_Target_3_Synonyms:
Zinc-alpha-2-glycoprotein precursor
Zn- alpha-2-GP
Zn-alpha-2-glycoprotein

# Drug_Target_3_Theoretical_pI:
5.66

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
Not Available

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
M34958

# Drug_Target_4_GenBank_ID_Protein:
Not Available

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
Not Available

# Drug_Target_4_Gene_Sequence:
>1155 bp
ATGGCCCCCAAAAGAAAAAGCGGCGTCTCTAAATGCGAGACAAAATGTACAAAGGCCTGT
CCAAGACCCGCACCCGTTCCCAAACTGCTTATTAAAGGGGGTATGGAGGTGCTGGACCTT
GTGACAGGGCCAGACAGTGTGACAGAAATAGAAGCTTTTCTGAACCCCAGAATGGGGCAG
CCACCCACCCCTGAAAGCCTAACAGAGGGAGGGCAATACTATGGTTGGAGCAGAGGGATT
AATTTGGCTACATCAGATACAGAGGATTCCCCAGGAAATAATACACTTCCCACATGGAGT
ATGGCAAAGCTCCAGCTTCCCATGCTCAATGAGGACCTCACCTGTGACACCCTACAAATG
TGGGAGGCAGTCTCAGTGAAAACCGAGGTGGTGGGCTCTGGCTCACTGTTAGATGTGCAT
GGGTTCAACAAACCCACAGATACAGTAAACACAAAAGGAATTTCCACTCCAGTGGAAGGC
AGCCAATATCATGTGTTTGCTGTGGGCGGGGAACCGCTTGACCTCCAGGGACTTGTGACA
GATGCCAGAACAAAATACAAGGAAGAAGGGGTAGTAACAATCAAAACAATCACAAAGAAG
GACATGGTCAACAAAGACCAAGTCCTGAATCCAATTAGCAAGGCCAAGCTGGATAAGGAC
GGAATGTATCCAGTTGAAATCTGGCATCCAGATCCAGCAAAAAATGAGAACACAAGGTAC
TTTGGCAATTACACTGGAGGCACAACAACTCCACCCGTCCTGCAGTTCACAAACACCCTG
ACAACTGTGCTCCTAGATGAAAATGGAGTTGGGCCCCTCTGTAAAGGAGAGGGCCTATAC
CTCTCCTGTGTAGATATAATGGGCTGGAGAGTTACAAGAAACTATGATGTCCATCACTGG
AGAGGGCTTCCCAGATATTTCAAAATCACCCTGAGAAAAAGATGGGTCAAAAATCCCTAT
CCCATGGCCTCCCTCATAAGTTCCCTTTTCAACAACATGCTCCCCCAAGTGCAGGGCCAA
CCCATGGAAGGGGAGAACACCCAGGTAGAGGAGGTTAGAGTGTATGATGGGACTGAACCT
GTACCGGGGGACCCTGATATGACGCGCTATGTTGACCGCTTTGGAAAAACAAAGACTGTA
TTTCCTGGAAATTAA

# Drug_Target_4_General_Function:
Involved in structural molecule activity

# Drug_Target_4_General_References:
1845896	Freund R, Garcea RL, Sahli R, Benjamin TL: A single-amino-acid substitution in polyomavirus VP1 correlates with plaque size and hemagglutination behavior. J Virol. 1991 Jan;65(1):350-5.
8177322	Stehle T, Yan Y, Benjamin TL, Harrison SC: Structure of murine polyomavirus complexed with an oligosaccharide receptor fragment. Nature. 1994 May 12;369(6476):160-3.
8805524	Stehle T, Harrison SC: Crystal structures of murine polyomavirus in complex with straight-chain and branched-chain sialyloligosaccharide receptor fragments. Structure. 1996 Feb 15;4(2):183-94.
9305654	Stehle T, Harrison SC: High-resolution structure of a polyomavirus VP1-oligosaccharide complex: implications for assembly and receptor binding. EMBO J. 1997 Aug 15;16(16):5139-48.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
5416

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
42506

# Drug_Target_4_Name:
Coat protein VP1

# Drug_Target_4_Number_of_Residues:
384

# Drug_Target_4_PDB_ID:
1SIE

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00718	Polyoma_coat

# Drug_Target_4_Protein_Sequence:
>Coat protein VP1
MAPKRKSGVSKCETKCTKACPRPAPVPKLLIKGGMEVLDLVTGPDSVTEIEAFLNPRMGQ
PPTPESLTEGGQYYGWSRGINLATSDTEDSPGNNTLPTWSMAKLQLPMLNEDLTCDTLQM
WEAVSVKTEVVGSGSLLDVHGFNKPTDTVNTKGISTPVEGSQYHVFAVGGEPLDLQGLVT
DARTKYKEEGVVTIKTITKKDMVNKDQVLNPISKAKLDKDGMYPVEIWHPDPAKNENTRY
FGNYTGGTTTPPVLQFTNTLTTVLLDENGVGPLCKGEGLYLSCVDIMGWRVTRNYDVHHW
RGLPRYFKITLRKRWVKNPYPMASLISSLFNNMLPQVQGQPMEGENTQVEEVRVYDGTEP
VPGDPDMTRYVDRFGKTKTVFPGN

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Not Available

# Drug_Target_4_SwissProt_ID:
P49302

# Drug_Target_4_SwissProt_Name:
VP1_POVMP

# Drug_Target_4_Synonyms:
Not Available

# Drug_Target_4_Theoretical_pI:
6.38

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Not Available

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
Not Available

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
X94484

# Drug_Target_5_GenBank_ID_Protein:
Not Available

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
L5

# Drug_Target_5_Gene_Sequence:
>1098 bp
ATGTCAAAGAGGCTCCGGGTGGAAGATGACTTCAACCCCGTCTACCCCTATGGCTACGCG
CGGAATCAGAATATCCCCTTCCTCACTCCCCCCTTTGTCTCCTCCGATGGATTCAAAAAC
TTCCCCCCTGGGGTACTGTCACTCAAACTGGCTGATCCAATCACCATTACCAATGGGGAT
GTATCCCTCAAGGTGGGAGGTGGTCTCACTTTGCAAGATGGAAGCCTAACTGTAAACCCT
AAGGCTCCACTGCAAGTTAATACTGATAAAAAACTTGAGCTTGCATATGATAATCCATTT
GAAAGTAGTGCTAATAAACTTAGTTTAAAAGTAGGACATGGATTAAAAGTATTAGATGAA
AAAAGTGCTGCGGGGTTAAAAGATTTAATTGGCAAACTTGTGGTTTTAACAGGAAAAGGA
ATAGGCACTGAAAATTTAGAAAATACAGATGGTAGCAGCAGAGGAATTGGTATAAATGTA
AGAGCAAGAGAAGGGTTGACATTTGACAATGATGGATACTTGGTAGCATGGAACCCAAAG
TATGACACGCGCACACTTTGGACAACACCAGACACATCTCCAAACTGCACAATTGCTCAA
GATAAGGACTCTAAACTCACTTTGGTACTTACAAAGTGTGGAAGTCAAATATTAGCTAAT
GTGTCTTTGATTGTGGTCGCAGGAAAGTACCACATCATAAATAATAAGACAAATCCAAAA
ATAAAAAGTTTTACTATTAAACTGCTATTTAATAAGAACGGAGTGCTTTTAGACAACTCA
AATCTTGGAAAAGCTTATTGGAACTTTAGAAGTGGAAATTCCAATGTTTCGACAGCTTAT
GAAAAAGCAATTGGTTTTATGCCTAATTTGGTAGCGTATCCAAAACCCAGTAATTCTAAA
AAATATGCAAGAGACATAGTTTATGGAACTATATATCTTGGTGGAAAACCTGATCAGCCA
GCAGTCATTAAAACTACCTTTAACCAAGAAACTGGATGTGAATACTCTATCACATTTAAC
TTTAGTTGGTCCAAAACCTATGAAAATGTTGAATTTGAAACCACCTCTTTTACCTTCTCC
TATATTGCCCAAGAATGA

# Drug_Target_5_General_Function:
Not Available

# Drug_Target_5_General_References:
9007080	Arnberg N, Mei Y, Wadell G: Fiber genes of adenoviruses with tropism for the eye and the genital tract. Virology. 1997 Jan 6;227(1):239-44.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
5418

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
40093

# Drug_Target_5_Name:
Fiber protein

# Drug_Target_5_Number_of_Residues:
365

# Drug_Target_5_PDB_ID:
1UXE

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00541	Adeno_knob
PF00608	Adeno_shaft

# Drug_Target_5_Protein_Sequence:
>Fiber protein
MSKRLRVEDDFNPVYPYGYARNQNIPFLTPPFVSSDGFKNFPPGVLSLKLADPITITNGD
VSLKVGGGLTLQDGSLTVNPKAPLQVNTDKKLELAYDNPFESSANKLSLKVGHGLKVLDE
KSAAGLKDLIGKLVVLTGKGIGTENLENTDGSSRGIGINVRAREGLTFDNDGYLVAWNPK
YDTRTLWTTPDTSPNCTIAQDKDSKLTLVLTKCGSQILANVSLIVVAGKYHIINNKTNPK
IKSFTIKLLFNKNGVLLDNSNLGKAYWNFRSGNSNVSTAYEKAIGFMPNLVAYPKPSNSK
KYARDIVYGTIYLGGKPDQPAVIKTTFNQETGCEYSITFNFSWSKTYENVEFETTSFTFS
YIAQE

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Not Available

# Drug_Target_5_SwissProt_ID:
Q64823

# Drug_Target_5_SwissProt_Name:
Q64823_9ADEN

# Drug_Target_5_Synonyms:
Not Available

# Drug_Target_5_Theoretical_pI:
9.35

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Endoplasmic reticulum

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
Not Available

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
CES1

# Drug_Target_6_GenBank_ID_Gene:
M73499

# Drug_Target_6_GenBank_ID_Protein:
Not Available

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
CES1

# Drug_Target_6_Gene_Sequence:
>1704 bp
ATGTGGCTCCGTGCCTTTATCCTGGCCACTCTCTCTGCTTCCGCGGCTTGGGGGCATCCG
TCCTCGCCACCTGTGGTGGACACCGTGCATGGCAAAGTGCTGGGGAAGTTCGTCAGCTTA
GAAGGATTTGCACAGCCTGTGGCCATTTTCCTGGGAATCCCTTTTGCCAAGCCGCCTCTT
GGACCCCTGAGGTTTACTCCACCGCAGCCTGCAGAACCATGGAGCTTTGTGAAGAATGCC
ACCTCGTACCCTCCTATGTGCACCCAAGATCCCAAGGCGGGGCAGTTACTCTCAGAGCTA
TTTACAAACCGAAAGGAGAACATTCCTCTCAAGCTTTCTGAAGACTGTCTTTACCTCAAT
ATTTACACTCCTGCTGACTTGACCAAGAAAAACAGGCTGCCGGTGATGGTGTGGATCCAC
GGAGGGGGGCTGATGGTGGGTGCGGCATCAACCTATGATGGGCTGGCCCTTGCTGCCCAT
GAAAACGTGGTGGTGGTGACCATTCAATATCGCCTGGGCATCTGGGGATTCTTCAGCACA
GGGGATGAACACAGCCGGGGGAACTGGGGTCACCTGGACCAGGTGGCTGCCCTGCGCTGG
GTCCAGGACAACATTGCCAGCTTTGGAGGGAACCCAGGCTCTGTGACCATCTTTGGAGAG
TCAGCGGGAGGAGAAAGTGTCTCTGTTCTTGTTTTGTCTCCATTGGCCAAGAACCTCTTC
CACCGGGCCATTTCTGAGAGTGGCGTGGCCCTCACTTCTGTTCTGGTGAAGAAAGGTGAT
GTCAAGCCCTTGGCTGAGCAAATTGCTATCACTGCTGGGTGCAAAACCACCACCTCTGCT
GTCATGGTTCACTGCCTGCGACAGAAGACGGAAGAGGAGCTCTTGGAGACGACATTGAAA
ATGAAATTCTTATCTCTGGACTTACAGGGAGACCCCAGAGAGAGTCAACCCCTTCTGGGC
ACTGTGATTGATGGGATGCTGCTGCTGAAAACACCTGAAGAGCTTCAAGCTGAAAGGAAT
TTCCACACTGTCCCCTACATGGTCGGAATTAACAAGCAGGAGTTTGGCTGGTTGATTCCA
ATGCAGTTGATGAGCTATCCACTCTCCGAAGGGCAACTGGACCAGAAGACAGCCATGTCA
CTCCTGTGGAAGTCCTATCCCCTTGTTTGCATTGCTAAGGAACTGATTCCAGAAGCCACT
GAGAAATACTTAGGAGGAACAGACGACACTGTCAAAAAGAAAGACCTGTTCCTGGACTTG
ATAGCAGATGTGATGTTTGGTGTCCCATCTGTGATTGTGGCCCGGAACCACAGAGATGCT
GGAGCACCCACCTACATGTATGAGTTTCAGTACCGTCCAAGCTTCTCATCAGACATGAAA
CCCAAGACGGTGATAGGAGACCACGGGGATGAGCTCTTCTCCGTCTTTGGGGCCCCATTT
TTAAAAGAGGGTGCCTCAGAAGAGGAGATCAGACTTAGCAAGATGGTGATGAAATTCTGG
GCCAACTTTGCTCGCAATGGAAACCCCAATGGGGAAGGGCTGCCCCACTGGCCAGAGTAC
AACCAGAAGGAAGGGTATCTGCAGATTGGTGCCAACACCCAGGCGGCCCAGAAGCTGAAG
GACAAAGAAGTAGCTTTCTGGACCAACCTCTTTGCCAAGAAGGCAGTGGAGAAGCCACCC
CAGACAGAACACATAGAGCTGTGA

# Drug_Target_6_General_Function:
Lipid transport and metabolism

# Drug_Target_6_General_References:
10518925	Mori M, Hosokawa M, Ogasawara Y, Tsukada E, Chiba K: cDNA cloning, characterization and stable expression of novel human brain carboxylesterase. FEBS Lett. 1999 Sep 10;458(1):17-22.
11015575	Ghosh S: Cholesteryl ester hydrolase in human monocyte/macrophage: cloning, sequencing, and expression of full-length cDNA. Physiol Genomics. 2000 Jan 24;2(1):1-8.
1918003	Munger JS, Shi GP, Mark EA, Chin DT, Gerard C, Chapman HA: A serine esterase released by human alveolar macrophages is closely related to liver microsomal carboxylesterases. J Biol Chem. 1991 Oct 5;266(28):18832-8.
1997784	Long RM, Calabrese MR, Martin BM, Pohl LR: Cloning and sequencing of a human liver carboxylesterase isoenzyme. Life Sci. 1991;48(11):PL43-9.
8049197	Becker A, Bottcher A, Lackner KJ, Fehringer P, Notka F, Aslanidis C, Schmitz G: Purification, cloning, and expression of a human enzyme with acyl coenzyme A: cholesterol acyltransferase activity, which is identical to liver carboxylesterase. Arterioscler Thromb. 1994 Aug;14(8):1346-55.
8218228	Kroetz DL, McBride OW, Gonzalez FJ: Glycosylation-dependent activity of baculovirus-expressed human liver carboxylesterases: cDNA cloning and characterization of two highly similar enzyme forms. Biochemistry. 1993 Nov 2;32(43):11606-17.
8406473	Shibata F, Takagi Y, Kitajima M, Kuroda T, Omura T: Molecular cloning and characterization of a human carboxylesterase gene. Genomics. 1993 Jul;17(1):76-82.

# Drug_Target_6_HGNC_ID:
HGNC:1863

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
4604

# Drug_Target_6_Locus:
16q13-q22.1

# Drug_Target_6_Molecular_Weight:
62522

# Drug_Target_6_Name:
Liver carboxylesterase 1

# Drug_Target_6_Number_of_Residues:
567

# Drug_Target_6_PDB_ID:
1MX1

# Drug_Target_6_Pathway:
Capecitabine Pathway	SMP00469
Heroin Pathway	SMP00407
Irinotecan Pathway	SMP00433

# Drug_Target_6_Pfam_Domain_Function:
PF00135	COesterase

# Drug_Target_6_Protein_Sequence:
>Liver carboxylesterase 1
MWLRAFILATLSASAAWGHPSSPPVVDTVHGKVLGKFVSLEGFAQPVAIFLGIPFAKPPL
GPLRFTPPQPAEPWSFVKNATSYPPMCTQDPKAGQLLSELFTNRKENIPLKLSEDCLYLN
IYTPADLTKKNRLPVMVWIHGGGLMVGAASTYDGLALAAHENVVVVTIQYRLGIWGFFST
GDEHSRGNWGHLDQVAALRWVQDNIASFGGNPGSVTIFGESAGGESVSVLVLSPLAKNLF
HRAISESGVALTSVLVKKGDVKPLAEQIAITAGCKTTTSAVMVHCLRQKTEEELLETTLK
MKFLSLDLQGDPRESQPLLGTVIDGMLLLKTPEELQAERNFHTVPYMVGINKQEFGWLIP
MQLMSYPLSEGQLDQKTAMSLLWKSYPLVCIAKELIPEATEKYLGGTDDTVKKKDLFLDL
IADVMFGVPSVIVARNHRDAGAPTYMYEFQYRPSFSSDMKPKTVIGDHGDELFSVFGAPF
LKEGASEEEIRLSKMVMKFWANFARNGNPNGEGLPHWPEYNQKEGYLQIGANTQAAQKLK
DKEVAFWTNLFAKKAVEKPPQTEHIEL

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
1-18

# Drug_Target_6_Specific_Function:
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl CoA ester

# Drug_Target_6_SwissProt_ID:
P23141

# Drug_Target_6_SwissProt_Name:
EST1_HUMAN

# Drug_Target_6_Synonyms:
ACAT
Acyl coenzyme A:cholesterol acyltransferase
Brain carboxylesterase hBr1
EC 3.1.1.1
Egasyn
HMSE
Liver carboxylesterase 1 precursor
Monocyte/macrophage serine esterase
Serine esterase 1
TGH
Triacylglycerol hydrolase

# Drug_Target_6_Theoretical_pI:
6.58

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Cytoplasmic

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
X04436

# Drug_Target_7_GenBank_ID_Protein:
40770

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
tetX

# Drug_Target_7_Gene_Sequence:
>3948 bp
ATGCCAATAACCATAAATAATTTTAGATATAGTGATCCTGTTAATAATGATACAATTATT
ATGATGGAGCCACCATACTGTAAGGGTCTAGATATCTATTATAAGGCTTTCAAAATAACA
GATCGTATTTGGATAGTGCCGGAAAGGTATGAATTTGGGACAAAACCTGAAGATTTTAAC
CCACCATCTTCATTAATAGAAGGTGCATCTGAGTATTACGATCCAAATTATTTAAGGACT
GATTCTGATAAAGATAGATTTTTACAAACCATGGTAAAACTGTTTAACAGAATTAAAAAC
AATGTAGCAGGTGAAGCCTTATTAGATAAGATAATAAATGCCATACCTTACCTTGGAAAT
TCATATTCCTTACTAGACAAGTTTGATACAAACTCTAATTCAGTATCTTTTAATTTATTA
GAACAAGACCCCAGTGGAGCAACTACAAAATCAGCAATGCTGACAAATTTAATAATATTT
GGACCTGGGCCTGTTTTAAATAAAAATGAGGTTAGAGGTATTGTATTGAGGGTAGATAAT
AAAAATTACTTCCCATGTAGAGATGGTTTTGGCTCAATAATGCAAATGGCATTTTGCCCA
GAATATGTACCTACCTTTGATAATGTAATAGAAAATATTACGTCACTCACTATTGGCAAA
AGCAAATATTTTCAAGATCCAGCATTACTATTAATGCACGAACTTATACATGTACTACAT
GGTTTATACGGAATGCAGGTATCAAGCCATGAAATTATTCCATCCAAACAAGAAATTTAT
ATGCAGCATACATATCCAATAAGTGCTGAAGAACTATTCACTTTTGGCGGACAGGATGCT
AATCTTATAAGTATTGATATAAAAAACGATTTATATGAAAAAACTTTAAATGATTATAAA
GCTATAGCTAACAAACTTAGTCAAGTCACTAGCTGCAATGATCCCAACATTGATATTGAT
AGCTACAAACAAATATATCAACAAAAATATCAATTCGATAAAGATAGCAATGGACAATAT
ATTGTAAATGAGGATAAATTTCAGATACTATATAATAGCATAATGTATGGTTTTACAGAG
ATTGAATTGGGAAAAAAATTTAATATAAAAACTAGACTTTCTTATTTTAGTATGAATCAT
GACCCTGTAAAAATTCCAAATTTATTAGATGATACAATTTACAATGATACAGAAGGATTT
AATATAGAAAGCAAAGATCTGAAATCTGAATATAAAGGACAAAATATGAGGGTAAATACA
AATGCTTTTAGAAATGTTGATGGATCAGGCCTAGTTTCAAAACTTATTGGCTTATGTAAA
AAAATTATACCACCAACAAATATAAGAGAAAATTTATATAATAGAACTGCATCATTAACA
GATTTAGGAGGAGAATTATGTATAAAAATTAAAAATGAAGATTTAACTTTTATAGCTGAA
AAAAATAGCTTTTCAGAAGAACCATTTCAAGATGAAATAGTTAGTTATAATACAAAAAAT
AAACCATTAAATTTTAATTATTCGCTAGATAAAATTATTGTAGATTATAATCTACAAAGT
AAAATTACATTACCTAATGATAGGACAACCCCAGTTACAAAAGGAATTCCATATGCTCCA
GAATATAAAAGTAATGCTGCAAGTACAATAGAAATACATAATATTGATGACAATACAATA
TATCAATATTTGTATGCTCAAAAATCTCCTACAACTCTACAAAGAATAACTATGACTAAT
TCTGTTGATGACGCATTAATAAATTCCACCAAAATATATTCATATTTTCCATCTGTAATC
AGTAAAGTTAACCAAGGTGCACAAGGAATTTTATTCTTACAGTGGGTGAGAGATATAATT
GATGATTTTACCAATGAATCTTCACAAAAAACTACTATTGATAAAATTTCAGATGTATCC
ACTATTGTTCCTTATATAGGACCCGCATTAAACATTGTAAAACAAGGCTATGAGGGAAAC
TTTATAGGCGCTTTAGAAACTACCGGAGTGGTTTTATTATTAGAATATATTCCAGAAATT
ACTTTACCAGTAATTGCAGCTTTATCTATAGCAGAAAGTAGCACACAAAAAGAAAAGATA
ATAAAAACAATAGATAACTTTTTAGAAAAAAGATATGAAAAATGGATTGAAGTATATAAA
CTAGTAAAAGCAAAATGGTTAGGCACAGTTAATACGCAATTCCAAAAAAGAAGTTATCAA
ATGTATAGATCTTTAGAATATCAAGTAGATGCAATAAAAAAAATAATAGACTATGAATAT
AAAATATATTCAGGACCTGATAAGGAACAAATTGCCGACGAAATTAATAATCTGAAAAAC
AAACTTGAAGAAAAGGCTAATAAAGCAATGATAAACATAAATATATTTATGAGGGAAAGT
TCTAGATCATTTTTAGTTAATCAAATGATTAACGAAGCTAAAAAGCAGTTATTAGAGTTT
GATACTCAAAGCAAAAATATTTTAATGCAGTATATAAAAGCAAATTCTAAATTTATAGGT
ATAACTGAACTAAAAAAATTAGAATCAAAAATAAACAAAGTTTTTTCAACACCAATTCCA
TTTTCTTATTCTAAAAATCTGGATTGTTGGGTTGATAATGAAGAAGATATAGATGTTATA
TTAAAAAAGAGTACAATTTTAAATTTAGATATTAATAATGATATTATATCAGATATATCT
GGGTTTAATTCATCTGTAATAACATATCCAGATGCTCAATTGGTGCCCGGAATAAATGGC
AAAGCAATACATTTAGTAAACAATGAATCTTCTGAAGTTATAGTGCATAAAGCTATGGAT
ATTGAATATAATGATATGTTTAATAATTTTACCGTTAGCTTTTGGTTGAGGGTTCCTAAA
GTATCTGCTAGTCATTTAGAACAATATGGCACAAATGAGTATTCAATAATTAGCTCTATG
AAAAAACATAGTCTATCAATAGGATCTGGTTGGAGTGTATCACTTAAAGGTAATAACTTA
ATATGGACTTTAAAAGATTCCGCGGGAGAAGTTAGACAAATAACTTTTAGGGATTTACCT
GATAAATTTAATGCTTATTTAGCAAATAAATGGGTTTTTATAACTATTACTAATGATAGA
TTATCTTCTGCTAATTTGTATATAAATGGAGTACTTATGGGAAGTGCAGAAATTACTGGT
TTAGGAGCTATTAGAGAGGATAATAATATAACATTAAAACTAGATAGATGTAATAATAAT
AATCAATACGTTTCTATTGATAAATTTAGGATATTTTGCAAAGCATTAAATCCAAAAGAG
ATTGAAAAATTATACACAAGTTATTTATCTATAACCTTTTTAAGAGACTTCTGGGGAAAC
CCTTTACGATATGATACAGAATATTATTTAATACCAGTAGCTTCTAGTTCTAAAGATGTT
CAATTGAAAAATATAACAGATTATATGTATTTGACAAATGCGCCATCGTATACTAACGGA
AAATTGAATATATATTATAGAAGGTTATATAATGGACTAAAATTTATTATAAAAAGATAT
ACACCTAATAATGAAATAGATTCTTTTGTTAAATCAGGTGATTTTATTAAATTATATGTA
TCATATAACAATAATGAGCACATTGTAGGTTATCCGAAAGATGGAAATGCCTTTAATAAT
CTTGATAGAATTCTAAGAGTAGGTTATAATGCCCCAGGTATCCCTCTTTATAAAAAAATG
GAAGCAGTAAAATTGCGTGATTTAAAAACCTATTCTGTACAACTTAAATTATATGATGAT
AAAAATGCATCTTTAGGACTAGTAGGTACCCATAATGGTCAAATAGGCAACGATCCAAAT
AGGGATATATTAATTGCAAGCAACTGGTACTTTAATCATTTAAAAGATAAAATTTTAGGA
TGTGATTGGTACTTTGTACCTACAGATGAAGGATGGACAAATGATTAA

# Drug_Target_7_General_Function:
Involved in metalloendopeptidase activity

# Drug_Target_7_General_References:
12552129	Bruggemann H, Baumer S, Fricke WF, Wiezer A, Liesegang H, Decker I, Herzberg C, Martinez-Arias R, Merkl R, Henne A, Gottschalk G: The genome sequence of Clostridium tetani, the causative agent of tetanus disease. Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1316-21. Epub 2003 Jan 27.
1331807	Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, DasGupta BR, Montecucco C: Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature. 1992 Oct 29;359(6398):832-5.
1396558	Schiavo G, Poulain B, Rossetto O, Benfenati F, Tauc L, Montecucco C: Tetanus toxin is a zinc protein and its inhibition of neurotransmitter release and protease activity depend on zinc. EMBO J. 1992 Oct;11(10):3577-83.
1935979	Krieglstein KG, Henschen AH, Weller U, Habermann E: Limited proteolysis of tetanus toxin. Relation to activity and identification of cleavage sites. Eur J Biochem. 1991 Nov 15;202(1):41-51.
2108021	Krieglstein K, Henschen A, Weller U, Habermann E: Arrangement of disulfide bridges and positions of sulfhydryl groups in tetanus toxin. Eur J Biochem. 1990 Feb 22;188(1):39-45.
3510187	Fairweather NF, Lyness VA, Pickard DJ, Allen G, Thomson RO: Cloning, nucleotide sequencing, and expression of tetanus toxin fragment C in Escherichia coli. J Bacteriol. 1986 Jan;165(1):21-7.
3536478	Eisel U, Jarausch W, Goretzki K, Henschen A, Engels J, Weller U, Hudel M, Habermann E, Niemann H: Tetanus toxin: primary structure, expression in E. coli, and homology with botulinum toxins. EMBO J. 1986 Oct;5(10):2495-502.
3774547	Fairweather NF, Lyness VA: The complete nucleotide sequence of tetanus toxin. Nucleic Acids Res. 1986 Oct 10;14(19):7809-12.
9334741	Umland TC, Wingert LM, Swaminathan S, Furey WF, Schmidt JJ, Sax M: Structure of the receptor binding fragment HC of tetanus neurotoxin. Nat Struct Biol. 1997 Oct;4(10):788-92.

# Drug_Target_7_HGNC_ID:
Not Available

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
2570

# Drug_Target_7_Locus:
Not Available

# Drug_Target_7_Molecular_Weight:
150684

# Drug_Target_7_Name:
Tetanus toxin

# Drug_Target_7_Number_of_Residues:
1315

# Drug_Target_7_PDB_ID:
Not Available

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF01742	Peptidase_M27
PF07951	Toxin_R_bind_C
PF07952	Toxin_trans
PF07953	Toxin_R_bind_N

# Drug_Target_7_Protein_Sequence:
>Tetanus toxin precursor
MPITINNFRYSDPVNNDTIIMMEPPYCKGLDIYYKAFKITDRIWIVPERYEFGTKPEDFN
PPSSLIEGASEYYDPNYLRTDSDKDRFLQTMVKLFNRIKNNVAGEALLDKIINAIPYLGN
SYSLLDKFDTNSNSVSFNLLEQDPSGATTKSAMLTNLIIFGPGPVLNKNEVRGIVLRVDN
KNYFPCRDGFGSIMQMAFCPEYVPTFDNVIENITSLTIGKSKYFQDPALLLMHELIHVLH
GLYGMQVSSHEIIPSKQEIYMQHTYPISAEELFTFGGQDANLISIDIKNDLYEKTLNDYK
AIANKLSQVTSCNDPNIDIDSYKQIYQQKYQFDKDSNGQYIVNEDKFQILYNSIMYGFTE
IELGKKFNIKTRLSYFSMNHDPVKIPNLLDDTIYNDTEGFNIESKDLKSEYKGQNMRVNT
NAFRNVDGSGLVSKLIGLCKKIIPPTNIRENLYNRTASLTDLGGELCIKIKNEDLTFIAE
KNSFSEEPFQDEIVSYNTKNKPLNFNYSLDKIIVDYNLQSKITLPNDRTTPVTKGIPYAP
EYKSNAASTIEIHNIDDNTIYQYLYAQKSPTTLQRITMTNSVDDALINSTKIYSYFPSVI
SKVNQGAQGILFLQWVRDIIDDFTNESSQKTTIDKISDVSTIVPYIGPALNIVKQGYEGN
FIGALETTGVVLLLEYIPEITLPVIAALSIAESSTQKEKIIKTIDNFLEKRYEKWIEVYK
LVKAKWLGTVNTQFQKRSYQMYRSLEYQVDAIKKIIDYEYKIYSGPDKEQIADEINNLKN
KLEEKANKAMININIFMRESSRSFLVNQMINEAKKQLLEFDTQSKNILMQYIKANSKFIG
ITELKKLESKINKVFSTPIPFSYSKNLDCWVDNEEDIDVILKKSTILNLDINNDIISDIS
GFNSSVITYPDAQLVPGINGKAIHLVNNESSEVIVHKAMDIEYNDMFNNFTVSFWLRVPK
VSASHLEQYGTNEYSIISSMKKHSLSIGSGWSVSLKGNNLIWTLKDSAGEVRQITFRDLP
DKFNAYLANKWVFITITNDRLSSANLYINGVLMGSAEITGLGAIREDNNITLKLDRCNNN
NQYVSIDKFRIFCKALNPKEIEKLYTSYLSITFLRDFWGNPLRYDTEYYLIPVASSSKDV
QLKNITDYMYLTNAPSYTNGKLNIYYRRLYNGLKFIIKRYTPNNEIDSFVKSGDFIKLYV
SYNNNEHIVGYPKDGNAFNNLDRILRVGYNAPGIPLYKKMEAVKLRDLKTYSVQLKLYDD
KNASLGLVGTHNGQIGNDPNRDILIASNWYFNHLKDKILGCDWYFVPTDEGWTND

# Drug_Target_7_Reaction:
Hydrolysis of -Gln76!Phe- bond in synaptobrevin (also known as neuronal vesicle-associated membrane protein, VAMP)

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Tetanus toxin acts by inhibiting neurotransmitter release. It binds to peripheral neuronal synapses, is internalized and moves by retrograde transport up the axon into the spinal cord where it can move between postsynaptic and presynaptic neurons. It inhibits neurotransmitter release by acting as a zinc endopeptidase that catalyzes the hydrolysis of the '76-Gln-|-Phe- 77' bond of synaptobrevin-2

# Drug_Target_7_SwissProt_ID:
P04958

# Drug_Target_7_SwissProt_Name:
TETX_CLOTE

# Drug_Target_7_Synonyms:
EC 3.4.24.68
Tentoxylysin
Tetanus toxin precursor

# Drug_Target_7_Theoretical_pI:
5.91

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Not Available

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
Not Available

# Drug_Target_8_GenBank_ID_Gene:
X00171

# Drug_Target_8_GenBank_ID_Protein:
48348

# Drug_Target_8_GeneCard_ID:
Not Available

# Drug_Target_8_Gene_Name:
ctxB

# Drug_Target_8_Gene_Sequence:
>375 bp
ATGATTAAATTAAAATTTGGTGTTTTTTTTACAGTTTTACTATCTTCAGCATATGCACAT
GGAACACCTCAAAATATTACTGATTTGTGTGCAGAATCACACAACACACAAATATATACG
CTAAATGATAAGATATTTTCGTATACAGAATCTCTAGCTGGAAAAAGAGAGATGGCTATC
ATTACTTTTAAGAATGGTGCAATTTTTCAAGTAGAAGTACCAAGTAGTCAACATATAGAT
TCACAAAAAAAAGCGATTGAAAGGATGAAGGATACCCTGAGGATTGCATATCTTACTGAA
GCTAAAGTCGAAAAGTTATGTGTATGGAATAATAAAACGCCTCATGCGATTGCCGCAATT
AGTATGGCAAATTAA

# Drug_Target_8_General_Function:
Not Available

# Drug_Target_8_General_References:
10952301	Heidelberg JF, Eisen JA, Nelson WC, Clayton RA, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Umayam L, Gill SR, Nelson KE, Read TD, Tettelin H, Richardson D, Ermolaeva MD, Vamathevan J, Bass S, Qin H, Dragoi I, Sellers P, McDonald L, Utterback T, Fleishmann RD, Nierman WC, White O, Salzberg SL, Smith HO, Colwell RR, Mekalanos JJ, Venter JC, Fraser CM: DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae. Nature. 2000 Aug 3;406(6795):477-83.
11447291	Aman AT, Fraser S, Merritt EA, Rodigherio C, Kenny M, Ahn M, Hol WG, Williams NA, Lencer WI, Hirst TR: A mutant cholera toxin B subunit that binds GM1- ganglioside but lacks immunomodulatory or toxic activity. Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8536-41. Epub 2001 Jul 10.
11880036	Pickens JC, Merritt EA, Ahn M, Verlinde CL, Hol WG, Fan E: Anchor-based design of improved cholera toxin and E. coli heat-labile enterotoxin receptor binding antagonists that display multiple binding modes. Chem Biol. 2002 Feb;9(2):215-24.
12405825	Zhang Z, Merritt EA, Ahn M, Roach C, Hou Z, Verlinde CL, Hol WG, Fan E: Solution and crystallographic studies of branched multivalent ligands that inhibit the receptor-binding of cholera toxin. J Am Chem Soc. 2002 Nov 6;124(44):12991-8.
13679513	Fujinaga Y, Wolf AA, Rodighiero C, Wheeler H, Tsai B, Allen L, Jobling MG, Rapoport T, Holmes RK, Lencer WI: Gangliosides that associate with lipid rafts mediate transport of cholera and related toxins from the plasma membrane to endoplasmic reticulm. Mol Biol Cell. 2003 Dec;14(12):4783-93. Epub 2003 Sep 17.
3214	Gill DM: The arrangement of subunits in cholera toxin. Biochemistry. 1976 Mar 23;15(6):1242-8.
6315707	Lockman H, Kaper JB: Nucleotide sequence analysis of the A2 and B subunits of Vibrio cholerae enterotoxin. J Biol Chem. 1983 Nov 25;258(22):13722-6.
6646234	Mekalanos JJ, Swartz DJ, Pearson GD, Harford N, Groyne F, de Wilde M: Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development. Nature. 1983 Dec 8-14;306(5943):551-7.
7658472	Zhang RG, Westbrook ML, Westbrook EM, Scott DL, Otwinowski Z, Maulik PR, Reed RA, Shipley GG: The 2.4 A crystal structure of cholera toxin B subunit pentamer: choleragenoid. J Mol Biol. 1995 Aug 25;251(4):550-62.
8003954	Merritt EA, Sarfaty S, van den Akker F, L'Hoir C, Martial JA, Hol WG: Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. Protein Sci. 1994 Feb;3(2):166-75.
8181723	Lebens M, Holmgren J: Structure and arrangement of the cholera toxin genes in Vibrio cholerae O139. FEMS Microbiol Lett. 1994 Apr 1;117(2):197-202.
903362	Lai CY: Determination of the primary structure of cholera toxin B subunit. J Biol Chem. 1977 Oct 25;252(20):7249-56.
903363	Kurosky A, Markel DE, Peterson JW: Covalent structure of the beta chain of cholera enterotoxin. J Biol Chem. 1977 Oct 25;252(20):7257-64.
9232653	Merritt EA, Sarfaty S, Jobling MG, Chang T, Holmes RK, Hirst TR, Hol WG: Structural studies of receptor binding by cholera toxin mutants. Protein Sci. 1997 Jul;6(7):1516-28.

# Drug_Target_8_HGNC_ID:
Not Available

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
2723

# Drug_Target_8_Locus:
Not Available

# Drug_Target_8_Molecular_Weight:
13957

# Drug_Target_8_Name:
Cholera enterotoxin subunit B

# Drug_Target_8_Number_of_Residues:
124

# Drug_Target_8_PDB_ID:
1S5F

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF01376	Enterotoxin_b

# Drug_Target_8_Protein_Sequence:
>Cholera enterotoxin subunit B precursor
MIKLKFGVFFTVLLSSAYAHGTPQNITDLCAEYHNTQIYTLNDKIFSYTESLAGKREMAI
ITFKNGAIFQVEVPGSQHIDSQKKAIERMKDTLRIAYLTEAKVEKLCVWNNKTPHAIAAI
SMAN

# Drug_Target_8_Reaction:
Not Available

# Drug_Target_8_Signals:
1-21

# Drug_Target_8_Specific_Function:
The B subunit pentameric ring directs the A subunit to its target by binding to the GM1 gangliosides present on the surface of the intestinal epithelial cells. It can bind five GM1 gangliosides. It has no toxic activity by itself

# Drug_Target_8_SwissProt_ID:
P01556

# Drug_Target_8_SwissProt_Name:
CHTB_VIBCH

# Drug_Target_8_Synonyms:
Cholera enterotoxin B chain
Cholera enterotoxin gamma chain
Cholera enterotoxin subunit B precursor
Choleragenoid

# Drug_Target_8_Theoretical_pI:
9.09

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Secreted protein

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
Not Available

# Drug_Target_9_GenBank_ID_Gene:
M81186

# Drug_Target_9_GenBank_ID_Protein:
144735

# Drug_Target_9_GeneCard_ID:
Not Available

# Drug_Target_9_Gene_Name:
botB

# Drug_Target_9_Gene_Sequence:
>3876 bp
ATGCCAGTTACAATAAATAATTTTAATTATAATGATCCTATTGATAATAATAATATTATT
ATGATGGAGCCTCCATTTGCGAGAGGTACGGGGAGATATTATAAAGCTTTTAAAATCACA
GATCGTATTTGGATAATACCGGAAAGATATACTTTTGGATATAAACCTGAGGATTTTAAT
AAAAGTTCCGGTATTTTTAATAGAGATGTTTGTGAATATTATGATCCAGATTACTTAAAT
ACTAATGATAAAAAGAATATATTTTTACAAACAATGATCAAGTTATTTAATAGAATCAAA
TCAAAACCATTGGGTGAAAAGTTATTAGAGATGATTATAAATGGTATACCTTATCTTGGA
GATAGACGTGTTCCACTCGAAGAGTTTAACACAAACATTGCTAGTGTAACTGTTAATAAA
TTAATCAGTAATCCAGGAGAAGTGGAGCGAAAAAAAGGTATTTTCGCAAATTTAATAATA
TTTGGACCTGGGCCAGTTTTAAATGAAAATGAGACTATAGATATAGGTATACAAAATCAT
TTTGCATCAAGGGAAGGCTTCGGGGGTATAATGCAAATGAAGTTTTGCCCAGAATATGTA
AGCGTATTTAATAATGTTCAAGAAAACAAAGGCGCAAGTATATTTAATAGACGTGGATAT
TTTTCAGATCCAGCCTTGATATTAATGCATGAACTTATACATGTTTTACATGGATTATAT
GGCATTAAAGTAGATGATTTACCAATTGTACCAAATGAAAAAAAATTTTTTATGCAATCT
ACAGATGCTATACAGGCAGAAGAACTATATACATTTGGAGGACAAGATCCCAGCATCATA
ACTCCTTCTACGGATAAAAGTATCTATGATAAAGTTTTGCAAAATTTTAGAGGGATAGTT
GATAGACTTAACAAGGTTTTAGTTTGCATATCAGATCCTAACATTAATATTAATATATAT
AAAAATAAATTTAAAGATAAATATAAATTCGTTGAAGATTCTGAGGGAAAATATAGTATA
GATGTAGAAAGTTTTGATAAATTATATAAAAGCTTAATGTTTGGTTTTACAGAAACTAAT
ATAGCAGAAAATTATAAAATAAAAACTAGAGCTTCTTATTTTAGTGATTCCTTACCACCA
GTAAAAATAAAAAATTTATTAGATAATGAAATCTATACTATAGAGGAAGGGTTTAATATA
TCTGATAAAGATATGGAAAAAGAATATAGAGGTCAGAATAAAGCTATAAATAAACAAGCT
TATGAAGAAATTAGCAAGGAGCATTTGGCTGTATATAAGATACAAATGTGTAAAAGTGTT
AAAGCTCCAGGAATATGTATTGATGTTGATAATGAAGATTTGTTCTTTATAGCTGATAAA
AATAGTTTTTCAGATGATTTATCTAAAAACGAAAGAATAGAATATAATACACAGAGTAAT
TATATAGAAAATGACTTCCCTATAAATGAATTAATTTTAGATACTGATTTAATAAGTAAA
ATAGAATTACCAAGTGAAAATACAGAATCACTTACTGATTTTAATGTAGATGTTCCAGTA
TATGAAAAACAACCCGCTATAAAAAAAATTTTTACAGATGAAAATACCATCTTTCAATAT
TTATACTCTCAGACATTTCCTCTAGATATAAGAGATATAAGTTTAACATCTTCATTTGAT
GATGCATTATTATTTTCTAACAAAGTTTATTCATTTTTTTCTATGGATTATATTAAAACT
GCTAATAAAGTGGTAGAAGCAGGATTATTTGCAGGTTGGGTGAAACAGATAGTAAATGAT
TTTGTAATCGAAGCTAATAAAAGCAATACTATGGATAAAATTGCAGATATATCTCTAATT
GTTCCTTATATAGGATTAGCTTTAAATGTAGGAAATGAAACAGCTAAAGGAAATTTTGAA
AATGCTTTTGAGATTGCAGGAGCCAGTATTCTACTAGAATTTATACCAGAACTTTTAATA
CCTGTAGTTGGAGCCTTTTTATTAGAATCATATATTGACAATAAAAATAAAATTATTAAA
ACAATAGATAATGCTTTAACTAAAAGAAATGAAAAATGGAGTGATATGTACGGATTAATA
GTAGCGCAATGGCTCTCAACAGTTAATACTCAATTTTATACAATAAAAGAGGGAATGTAT
AAGGCTTTAAATTATCAAGCACAAGCATTGGAAGAAATAATAAAATACAGATATAATATA
TATTCTGAAAAAGAAAAGTCAAATATTAACATCGATTTTAATGATATAAATTCTAAACTT
AATGAGGGTATTAACCAAGCTATAGATAATATAAATAATTTTATAAATGGATGTTCTGTA
TCATATTTAATGAAAAAAATGATTCCATTAGCTGTAGAAAAATTACTAGACTTTGATAAT
ACTCTCAAAAAAAATTTGTTAAATTATATAGATGAAAATAAATTATATTTGATTGGAAGT
GCAGAATATGAAAAATCAAAAGTAAATAAATACTTGAAAACCATTATGCCGTTTGATCTT
TCAATATATACCAATGATACAATACTAATAGAAATGTTTAATAAATATAATAGCGAAATT
TTAAATAATATTATCTTAAATTTAAGATATAAGGATAATAATTTAATAGATTTATCAGGA
TATGGGGCAAAGGTAGAGGTATATGATGGAGTCGAGCTTAATGATAAAAATCAATTTAAA
TTAACTAGTTCAGCAAATAGTAAGATTAGAGTGACTCAAAATCAGAATATCATATTTAAT
AGTGTGTTCCTTGATTTTAGCGTTAGCTTTTGGATAAGAATACCTAAATATAAGAATGAT
GGTATACAAAATTATATTCATAATGAATATACAATAATTAATTGTATGAAAAATAATTCG
GGCTGGAAAATATCTATTAGGGGTAATAGGATAATATGGACTTTAATTGATATAAATGGA
AAAACCAAATCGGTATTTTTTGAATATAACATAAGAGAAGATATATCAGAGTATATAAAT
AGATGGTTTTTTGTAACTATTACTAATAATTTGAATAACGCTAAAATTTATATTAATGGT
AAGCTAGAATCAAATACAGATATTAAAGATATAAGAGAAGTTATTGCTAATGGTGAAATA
ATATTTAAATTAGATGGTGATATAGATAGAACACAATTTATTTGGATGAAATATTTCAGT
ATTTTTAATACGGAATTAAGTCAATCAAATATTGAAGAAAGATATAAAATTCAATCATAT
AGCGAATATTTAAAAGATTTTTGGGGAAATCCTTTAATGTACAATAAAGAATATTATATG
TTTAATGCGGGGAATAAAAATTCATATATTAAACTAAAGAAAGATTCACCTGTAGGTGAA
ATTTTAACACGTAGCAAATATAATCAAAATTCTAAATATATAAATTATAGAGATTTATAT
ATTGGAGAAAAATTTATTATAAGAAGAAAGTCAAATTCTCAATCTATAAATGATGATATA
GTTAGAAAAGAAGATTATATATATCTAGATTTTTTTAATTTAAATCAAGAGTGGAGAGTA
TATACCTATAAATATTTTAAGAAAGAGGAAGAAAAATTGTTTTTAGCTCCTATAAGTGAT
TCTGATGAGTTTTACAATACTATACAAATAAAAGAATATGATGAACAGCCAACATATAGT
TGTCAGTTGCTTTTTAAAAAAGATGAAGAAAGTACTGATGAGATAGGATTGATTGGTATT
CATCGTTTCTACGAATCTGGAATTGTATTTGAAGAGTATAAAGATTATTTTTGTATAAGT
AAATGGTACTTAAAAGAGGTAAAAAGGAAACCATATAATTTAAAATTGGGATGTAATTGG
CAGTTTATTCCTAAAGATGAAGGGTGGACTGAATAA

# Drug_Target_9_General_Function:
Involved in metalloendopeptidase activity

# Drug_Target_9_General_References:
1331807	Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, DasGupta BR, Montecucco C: Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature. 1992 Oct 29;359(6398):832-5.
1429690	Schiavo G, Rossetto O, Santucci A, DasGupta BR, Montecucco C: Botulinum neurotoxins are zinc proteins. J Biol Chem. 1992 Nov 25;267(33):23479-83.
1514783	Whelan SM, Elmore MJ, Bodsworth NJ, Brehm JK, Atkinson T, Minton NP: Molecular cloning of the Clostridium botulinum structural gene encoding the type B neurotoxin and determination of its entire nucleotide sequence. Appl Environ Microbiol. 1992 Aug;58(8):2345-54.
3139097	Dasgupta BR, Datta A: Botulinum neurotoxin type B (strain 657): partial sequence and similarity with tetanus toxin. Biochimie. 1988 Jun;70(6):811-7.
3888113	Schmidt JJ, Sathyamoorthy V, DasGupta BR: Partial amino acid sequences of botulinum neurotoxins types B and E. Arch Biochem Biophys. 1985 May 1;238(2):544-8.
8408542	Campbell KD, Collins MD, East AK: Gene probes for identification of the botulinal neurotoxin gene and specific identification of neurotoxin types B, E, and F. J Clin Microbiol. 1993 Sep;31(9):2255-62.

# Drug_Target_9_HGNC_ID:
Not Available

# Drug_Target_9_HPRD_ID:
Not Available

# Drug_Target_9_ID:
2324

# Drug_Target_9_Locus:
Not Available

# Drug_Target_9_Molecular_Weight:
150804

# Drug_Target_9_Name:
Botulinum neurotoxin type B

# Drug_Target_9_Number_of_Residues:
1291

# Drug_Target_9_PDB_ID:
1S0G

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF01742	Peptidase_M27
PF07951	Toxin_R_bind_C
PF07952	Toxin_trans
PF07953	Toxin_R_bind_N

# Drug_Target_9_Protein_Sequence:
>Botulinum neurotoxin type B precursor
MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFN
KSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLG
DRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNH
FASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLY
GIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIV
DRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETN
IAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQA
YEEISKEHLAVYKIQMCKSVKAPGICIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSN
YIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQY
LYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVND
FVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLI
PVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMY
KALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSV
SYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDL
SIYTNDTILIEMFNKYNSEILNNIILNLRYKDNNLIDLSGYGAKVEVYDGVELNDKNQFK
LTSSANSKIRVTQNQNIIFNSVFLDFSVSFWIRIPKYKNDGIQNYIHNEYTIINCMKNNS
GWKISIRGNRIIWTLIDINGKTKSVFFEYNIREDISEYINRWFFVTITNNLNNAKIYING
KLESNTDIKDIREVIANGEIIFKLDGDIDRTQFIWMKYFSIFNTELSQSNIEERYKIQSY
SEYLKDFWGNPLMYNKEYYMFNAGNKNSYIKLKKDSPVGEILTRSKYNQNSKYINYRDLY
IGEKFIIRRKSNSQSINDDIVRKEDYIYLDFFNLNQEWRVYTYKYFKKEEEKLFLAPISD
SDEFYNTIQIKEYDEQPTYSCQLLFKKDEESTDEIGLIGIHRFYESGIVFEEYKDYFCIS
KWYLKEVKRKPYNLKLGCNWQFIPKDEGWTE

# Drug_Target_9_Reaction:
Limited hydrolysis of proteins of the neuroexocytosis apparatus, synaptobrevin (also known as neuronal vesicle-associated membrane protein, VAMP), synaptosome-associated protein of 25 kDa (SNAP25) or syntaxin. No detected action on small molecule substrates

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
Botulinum toxin acts by inhibiting neurotransmitter release. It binds to peripheral neuronal synapses, is internalized and moves by retrograde transport up the axon into the spinal cord where it can move between postsynaptic and presynaptic neurons. It inhibits neurotransmitter release by acting as a zinc endopeptidase that cleaves the '76-Gln-|-Phe-77' bond of synaptobrevin-2

# Drug_Target_9_SwissProt_ID:
P10844

# Drug_Target_9_SwissProt_Name:
BXB_CLOBO

# Drug_Target_9_Synonyms:
BoNT/B
Bontoxilysin-B
Botulinum neurotoxin type B precursor
EC 3.4.24.69

# Drug_Target_9_Theoretical_pI:
4.97

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB03721
